{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T20:04:20Z","timestamp":1790366660128,"version":"4.1.0"},"reference-count":427,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T00:00:00Z","timestamp":1785974400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010905","name":"Major Research Plan of National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82030110"],"award-info":[{"award-number":["82030110"]}],"id":[{"id":"10.13039\/501100010905","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010905","name":"Major Research Plan of National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82330117"],"award-info":[{"award-number":["82330117"]}],"id":[{"id":"10.13039\/501100010905","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82304618"],"award-info":[{"award-number":["82304618"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82304485"],"award-info":[{"award-number":["82304485"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["pharmrev.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Reviews"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.pharmr.2026.100155","type":"journal-article","created":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T06:32:06Z","timestamp":1786084326000},"page":"100155","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Recombinant protein drug metabolism and pharmacokinetics"],"prefix":"10.1016","volume":"78","author":[{"given":"Jie-Bing","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huan-Yu","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhu-Wei","family":"Miao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8176-3434","authenticated-orcid":false,"given":"Chao-Yu","family":"Miao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.pharmr.2026.100155_bib1","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1038\/s41587-022-01582-x","article-title":"Biopharmaceutical benchmarks 2022","volume":"40","author":"Walsh","year":"2022","journal-title":"Nat Biotechnol"},{"issue":"12","key":"10.1016\/j.pharmr.2026.100155_bib2","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1038\/nbt.4305","article-title":"Biopharmaceutical benchmarks 2018","volume":"36","author":"Walsh","year":"2018","journal-title":"Nat Biotechnol"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100155_bib3","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S1016-8478(23)25245-0","article-title":"Antibody engineering for the development of therapeutic antibodies","volume":"20","author":"Kim","year":"2005","journal-title":"Mol Cells"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100155_bib4","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1586\/14737140.3.6.767","article-title":"Rituximab (Rituxan\/MabThera): the first decade (1993-2003)","volume":"3","author":"Grillo-L\u00f3pez","year":"2003","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.pharmr.2026.100155_bib5","doi-asserted-by":"crossref","first-page":"139","DOI":"10.2147\/BTT.S207246","article-title":"Remicade(infliximab): 20 years of contributions to science and medicine","volume":"13","author":"Melsheimer","year":"2019","journal-title":"Biol Targets Ther"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100155_bib6","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1586\/era.11.178","article-title":"Cetuximab in non-small-cell lung cancer","volume":"12","author":"Carillio","year":"2012","journal-title":"Expert Rev Anticancer Ther"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100155_bib7","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1007\/s40265-024-02056-x","article-title":"Zolbetuximab: first approval","volume":"84","author":"Keam","year":"2024","journal-title":"Drugs"},{"key":"10.1016\/j.pharmr.2026.100155_bib8","first-page":"1187","article-title":"Review of daclizumab and its therapeutic potential in the treatment of relapsing-remitting multiple sclerosis","volume":"7","author":"Reardon","year":"2013","journal-title":"Drug Des Dev Ther"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100155_bib9","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1634\/theoncologist.2012-0003","article-title":"Bevacizumab-based therapies in the first-line treatment of metastatic colorectal cancer","volume":"17","author":"Strickler","year":"2012","journal-title":"Oncologist"},{"issue":"16","key":"10.1016\/j.pharmr.2026.100155_bib10","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1007\/s40265-018-1002-7","article-title":"Galcanezumab: first global approval","volume":"78","author":"Lamb","year":"2018","journal-title":"Drugs"},{"issue":"16","key":"10.1016\/j.pharmr.2026.100155_bib11","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1007\/s40265-020-01405-w","article-title":"Tafasitamab: first approval","volume":"80","author":"Hoy","year":"2020","journal-title":"Drugs"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100155_bib12","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1345\/aph.1S013","article-title":"Ranibizumab: the first vascular endothelial growth factor inhibitor approved for the treatment of diabetic macular edema","volume":"47","author":"Evoy","year":"2013","journal-title":"Ann Pharmacother"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100155_bib13","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1158\/1078-0432.CCR-20-3474","article-title":"FDA approval summary: pertuzumab, trastuzumab, and hyaluronidase-zzxf injection for subcutaneous use in patients with HER2-positive breast cancer","volume":"27","author":"Gao","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100155_bib14","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1007\/s40265-022-01711-5","article-title":"Sutimlimab: first approval","volume":"82","author":"Dhillon","year":"2022","journal-title":"Drugs"},{"issue":"16","key":"10.1016\/j.pharmr.2026.100155_bib15","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1007\/s40265-014-0314-5","article-title":"Pembrolizumab: first global approval","volume":"74","author":"Poole","year":"2014","journal-title":"Drugs"},{"issue":"12","key":"10.1016\/j.pharmr.2026.100155_bib16","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1358\/dot.2014.50.12.2235103","article-title":"Nivolumab","volume":"50","author":"Fulchiero","year":"2014","journal-title":"Drugs Today (Barc)"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100155_bib17","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1080\/21678707.2017.1279967","article-title":"Adalimumab for the treatment of non-infectious uveitis: an updated review","volume":"5","author":"Kubaisi","year":"2017","journal-title":"Expert Opin Orphan Drugs"},{"issue":"12","key":"10.1016\/j.pharmr.2026.100155_bib18","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1007\/s40265-014-0258-9","article-title":"Etanercept: a review of its use in autoimmune inflammatory diseases","volume":"74","author":"Scott","year":"2014","journal-title":"Drugs"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100155_bib19","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s40259-017-0217-6","article-title":"Golimumab: a review in inflammatory arthritis","volume":"31","author":"Frampton","year":"2017","journal-title":"BioDrugs"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100155_bib20","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1007\/s40265-025-02187-9","article-title":"Catumaxomab: first approval","volume":"85","author":"Syed","year":"2025","journal-title":"Drugs"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100155_bib21","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s40265-015-0356-3","article-title":"Blinatumomab: first global approval","volume":"75","author":"Sanford","year":"2015","journal-title":"Drugs"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100155_bib22","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1055\/a-1727-1384","article-title":"Emicizumab for all pediatric patients with severe hemophilia A","volume":"42","author":"Wieland","year":"2022","journal-title":"Hamostaseologie"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100155_bib23","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1007\/s40265-022-01713-3","article-title":"Faricimab: first approval","volume":"82","author":"Shirley","year":"2022","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100155_bib24","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2024.2443538","article-title":"Antibodies to watch in 2025","volume":"17","author":"Crescioli","year":"2025","journal-title":"mAbs"},{"issue":"suppl 10A","key":"10.1016\/j.pharmr.2026.100155_bib25","doi-asserted-by":"crossref","first-page":"16S","DOI":"10.1016\/j.amjmed.2005.07.029","article-title":"Evaluating existing recommendations for hepatitis A and B vaccination","volume":"118","author":"Poland","year":"2005","journal-title":"Am J Med"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100155_bib26","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1111\/j.1750-2659.2008.00053.x","article-title":"FluBlok, a recombinant hemagglutinin influenza vaccine","volume":"2","author":"Cox","year":"2008","journal-title":"Influ Other Respir Viruses"},{"issue":"12 suppl 2","key":"10.1016\/j.pharmr.2026.100155_bib27","doi-asserted-by":"crossref","first-page":"S367","DOI":"10.1093\/infdis\/jiaa621","article-title":"Human papillomavirus vaccines","volume":"224","author":"Markowitz","year":"2021","journal-title":"J Infect Dis"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100155_bib28","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/s41392-022-00996-y","article-title":"COVID-19 vaccine development: milestones, lessons and prospects","volume":"7","author":"Li","year":"2022","journal-title":"Signal Transduct Target Ther"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100155_bib29","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1034\/j.1600-0897.2001.d01-25.x","article-title":"Successful ovulation induction, conception, and normal delivery after chronic therapy with etanercept: a recombinant fusion anti-cytokine treatment for rheumatoid arthritis","volume":"46","author":"Sills","year":"2001","journal-title":"Am J Reprod Immunol"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100155_bib30","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s40123-013-0015-2","article-title":"Aflibercept for the treatment of age-related macular degeneration","volume":"2","author":"Trichonas","year":"2013","journal-title":"Ophthalmol Ther"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100155_bib31","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1007\/s40265-017-0775-4","article-title":"Abatacept: a review in rheumatoid arthritis","volume":"77","author":"Blair","year":"2017","journal-title":"Drugs"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100155_bib32","doi-asserted-by":"crossref","first-page":"307","DOI":"10.2165\/00003495-200969030-00006","article-title":"Romiplostim","volume":"69","author":"Frampton","year":"2009","journal-title":"Drugs"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100155_bib33","first-page":"579","article-title":"Albiglutide, an albumin-based fusion of glucagon-like peptide 1 for the potential treatment of type 2 diabetes","volume":"11","author":"Tomkin","year":"2009","journal-title":"Curr Opin Mol Ther"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100155_bib34","doi-asserted-by":"crossref","first-page":"2","DOI":"10.2174\/1389203722666211210115040","article-title":"Advanced protein drugs and formulations","volume":"23","author":"Benedini","year":"2022","journal-title":"Curr Protein Pept Sci"},{"key":"10.1016\/j.pharmr.2026.100155_bib35","doi-asserted-by":"crossref","first-page":"107","DOI":"10.2147\/BTT.S38387","article-title":"Biologics: the role of delivery systems in improved therapy","volume":"8","author":"Skalko-Basnet","year":"2014","journal-title":"Biol Targets Ther"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100155_bib36","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3390\/biom12010003","article-title":"Recombinant proteins-based strategies in bone tissue engineering","volume":"12","author":"Paulini","year":"2021","journal-title":"Biomolecules"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100155_bib37","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.drudis.2014.09.003","article-title":"An overview of FDA-approved biologics medicines","volume":"20","author":"Kinch","year":"2015","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.pharmr.2026.100155_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2023.114904","article-title":"Strategies for overcoming protein and peptide instability in biodegradable drug delivery systems","volume":"199","author":"Shi","year":"2023","journal-title":"Adv Drug Deliv Rev"},{"issue":"9","key":"10.1016\/j.pharmr.2026.100155_bib39","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/j.yexcr.2011.02.013","article-title":"Introduction to current and future protein therapeutics: a protein engineering perspective","volume":"317","author":"Carter","year":"2011","journal-title":"Exp Cell Res"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100155_bib40","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1517\/17460441.2010.521496","article-title":"Advances in targeted therapeutic agents","volume":"5","author":"Nicolaides","year":"2010","journal-title":"Expert Opin Drug Discov"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100155_bib41","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1080\/1061186X.2019.1669043","article-title":"Protein drug delivery: current dosage form profile and formulation strategies","volume":"28","author":"Geraldes","year":"2019","journal-title":"J Drug Target"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100155_bib42","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S0958-1669(02)00352-X","article-title":"Pharmacokinetics and biodistribution of genetically engineered antibodies","volume":"13","author":"Batra","year":"2002","journal-title":"Curr Opin Biotechnol"},{"key":"10.1016\/j.pharmr.2026.100155_bib43","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.jconrel.2019.02.016","article-title":"Current strategies in extending half-lives of therapeutic proteins","volume":"301","author":"Zaman","year":"2019","journal-title":"J Control Release"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100155_bib44","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1124\/pharmrev.124.001173","article-title":"Roles of individual human cytochrome P450 enzymes in drug metabolism","volume":"76","author":"Guengerich","year":"2024","journal-title":"Pharmacol Rev"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100155_bib45","first-page":"E579","article-title":"Pharmacokinetics of insulin-like growth factor I in hypopituitarism: correlation with binding proteins","volume":"277","author":"Mauras","year":"1999","journal-title":"Am J Physiol"},{"issue":"suppl 391","key":"10.1016\/j.pharmr.2026.100155_bib46","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1651-2227.1993.tb12918.x","article-title":"Pharmacokinetics of recombinant human insulin-like growth factor I given subcutaneously to healthy volunteers and to patients with growth hormone receptor deficiency","volume":"82","author":"Grahn\u00e9n","year":"1993","journal-title":"Acta Paediatr Suppl"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100155_bib47","doi-asserted-by":"crossref","first-page":"161","DOI":"10.5414\/CPP45161","article-title":"Transgenic avian-derived recombinant human interferon-alpha2b (AVI-005) in healthy subjects: an open-label, single-dose, controlled study","volume":"45","author":"Patel","year":"2007","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100155_bib48","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/j.1742-7843.2011.00768.x","article-title":"Safety, tolerability, pharmacokinetics and pharmacodynamics of recombinant human parathyroid hormone after single- and multiple-dose subcutaneous administration in healthy Chinese volunteers","volume":"110","author":"Liu","year":"2011","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100155_bib49","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1002\/jps.2600840708","article-title":"Pharmacokinetics of recombinant human granulocyte-macrophage colony-stimulating factor in children after intravenous and subcutaneous administration","volume":"84","author":"Stute","year":"1995","journal-title":"J Pharm Sci"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100155_bib50","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1046\/j.1365-2125.1998.00036.x","article-title":"Pharmacokinetics of recombinant human interleukin-2 in advanced renal cell carcinoma patients following subcutaneous application","volume":"46","author":"Kirchner","year":"1998","journal-title":"Br J Clin Pharmacol"},{"issue":"12","key":"10.1016\/j.pharmr.2026.100155_bib51","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1016\/0959-8049(93)90108-R","article-title":"Recombinant human interleukin-4 (rhu IL-4) administered by the intravenous and subcutaneous routes in patients with advanced cancer-a phase I toxicity study and pharmacokinetic analysis","volume":"29","author":"Prendiville","year":"1993","journal-title":"Eur J Cancer"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100155_bib52","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1046\/j.1365-2125.1997.00605.x","article-title":"Pharmacokinetics of recombinant human interleukin-11 (rhIL-11) in healthy male subjects","volume":"43","author":"Aoyama","year":"1997","journal-title":"Br J Clin Pharmacol"},{"issue":"9","key":"10.1016\/j.pharmr.2026.100155_bib53","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1182\/blood.V76.9.1718.1718","article-title":"Pharmacokinetics and effects of recombinant human erythropoietin after intravenous and subcutaneous injections in healthy volunteers","volume":"76","author":"McMahon","year":"1990","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100155_bib54","first-page":"215","article-title":"Evaluation of the pharmacokinetics of two recombinant human erythropoietin preparations: epoetin zeta and epoetin alfa. 1st Communication: a monocentric, open, randomized, single dose, two-period crossover trial in healthy volunteers","volume":"58","author":"Kirkov","year":"2008","journal-title":"Arzneim-Forsch"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100155_bib55","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1111\/fcp.12869","article-title":"Pharmacokinetic and pharmacodynamic study of three products of epoetin alfa as single subcutaneous dose in healthy volunteers","volume":"37","author":"di Girolamo","year":"2023","journal-title":"Fundam Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100155_bib56","first-page":"135","article-title":"Pharmacokinetics of erythropoietin following single-dose subcutaneous administration in preterm infants","volume":"70","author":"Krishnan","year":"1996","journal-title":"Biol Neonate"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100155_bib57","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/S0022-3476(05)83559-0","article-title":"Single-dose pharmacokinetics of recombinant human erythropoietin in preterm infants after intravenous and subcutaneous administration","volume":"122","author":"Brown","year":"1993","journal-title":"J Pediatr"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100155_bib58","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1530\/EJE-09-1101","article-title":"Bioequivalence between novel ready-to-use liquid formulations of the recombinant human GH Omnitrope and the original lyophilized formulations for reconstitution of Omnitrope and Genotropin","volume":"162","author":"Fuhr","year":"2010","journal-title":"Eur J Endocrinol"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100155_bib59","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1177\/0091270009359005","article-title":"Bioequivalence studies of omnitrope, the first biosimilar\/rhGH follow-on protein: two comparative phase 1 randomized studies and population pharmacokinetic analysis","volume":"50","author":"Stanhope","year":"2010","journal-title":"J Clin Pharmacol"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100155_bib60","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0015-0282(16)56645-X","article-title":"Clinical pharmacology of recombinant human follicle-stimulating hormone. II. Single doses and steady state pharmacokinetics","volume":"61","author":"le Contonnec","year":"1994","journal-title":"Fertil Steril"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100155_bib61","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/clpt.1989.120","article-title":"Pharmacokinetics and systemic effects of tissue-type plasminogen activator in normal subjects","volume":"46","author":"Tanswell","year":"1989","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100155_bib62","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/0735-1097(92)90297-Z","article-title":"Pharmacokinetics and fibrin specificity of alteplase during accelerated infusions in acute myocardial infarction","volume":"19","author":"Tanswell","year":"1992","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100155_bib63","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1136\/hrt.66.2.134","article-title":"A pilot study of the efficacy and safety of bolus administration of alteplase in acute myocardial infarction","volume":"66","author":"Gemmill","year":"1991","journal-title":"Br Heart J"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100155_bib64","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s40360-023-00673-y","article-title":"A phase I study comparing the biosimilarity of the pharmacokinetics and safety of recombinant humanized anti-vascular endothelial growth factor monoclonal antibody injection with Avastin\u00ae in healthy Chinese male subjects","volume":"24","author":"Li","year":"2023","journal-title":"BMC Pharmacol Toxicol"},{"issue":"13","key":"10.1016\/j.pharmr.2026.100155_bib65","doi-asserted-by":"crossref","first-page":"4810","DOI":"10.1158\/1078-0432.CCR-04-2329","article-title":"A phase I trial of humanized monoclonal antibody A33 in patients with colorectal carcinoma: biodistribution, pharmacokinetics, and quantitative tumor uptake","volume":"11","author":"Scott","year":"2005","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100155_bib66","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1007\/s40259-024-00679-w","article-title":"Pharmacokinetics, safety, and immunogenicity of a biosimilar of Nivolumab (LY01015): a randomized, double-blind, parallel-controlled phase I clinical trial in healthy Chinese male subjects","volume":"38","author":"Wang","year":"2024","journal-title":"BioDrugs"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100155_bib67","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1080\/14712598.2023.2178298","article-title":"Pharmacokinetics, pharmacodynamics, safety and immunogenicity of recombinant, fully human anti-RANKL monoclonal antibody (MW031) versus denosumab in Chinese healthy subjects: a single-center, randomized, double-blind, single-dose, parallel-controlled trial","volume":"23","author":"Guo","year":"2023","journal-title":"Expert Opin Biol Ther"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100155_bib68","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1080\/14712598.2021.1988567","article-title":"A randomized, double-blind, single-dose, single-center, parallel phase I clinical study comparing the pharmacokinetics, immunogenicity, safety, and tolerance of pertuzumab injection and Perjeta\u00ae in healthy Chinese male subjects","volume":"22","author":"Liu","year":"2022","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.pharmr.2026.100155_bib69","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.jconrel.2018.08.001","article-title":"Subcutaneous delivery of monoclonal antibodies: how do we get there?","volume":"286","author":"Viola","year":"2018","journal-title":"J Control Release"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100155_bib70","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1080\/17425247.2017.1395853","article-title":"Strategies and industrial perspectives to improve oral absorption of biological macromolecules","volume":"15","author":"Liu","year":"2017","journal-title":"Expert Opin Drug Deliv"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100155_bib71","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1080\/1061186X.2018.1486406","article-title":"Advance in oral delivery systems for therapeutic protein","volume":"27","author":"He","year":"2019","journal-title":"J Drug Target"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100155_bib72","doi-asserted-by":"crossref","first-page":"237","DOI":"10.3109\/10717544.2013.819611","article-title":"Oral delivery of therapeutic proteins and peptides: a review on recent developments","volume":"20","author":"Gupta","year":"2013","journal-title":"Drug Deliv"},{"key":"10.1016\/j.pharmr.2026.100155_bib73","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2020.107537","article-title":"Approaches to improve intestinal and transmucosal absorption of peptide and protein drugs","volume":"211","author":"Yamamoto","year":"2020","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.pharmr.2026.100155_bib74","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2021.114097","article-title":"Oral delivery of therapeutic peptides and proteins: technology landscape of lipid-based nanocarriers","volume":"182","author":"Haddadzadegan","year":"2022","journal-title":"Adv Drug Deliv Rev"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100155_bib75","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1007\/s11154-022-09735-8","article-title":"A new era for oral peptides: SNAC and the development of oral semaglutide for the treatment of type 2 diabetes","volume":"23","author":"Aroda","year":"2022","journal-title":"Rev Endocr Metab Disord"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100155_bib76","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1111\/dom.14901","article-title":"Oral insulin (ORMD-0801) in type 2 diabetes mellitus: a dose-finding 12-week randomized placebo-controlled study","volume":"25","author":"Eldor","year":"2022","journal-title":"Diabetes Obes Metab"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100155_bib77","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1111\/dom.14499","article-title":"Efficacy and safety of 28-day treatment with oral insulin (ORMD-0801) in patients with type 2 diabetes: a randomized, placebo-controlled trial","volume":"23","author":"Eldor","year":"2021","journal-title":"Diabetes Obes Metab"},{"issue":"1-2","key":"10.1016\/j.pharmr.2026.100155_bib78","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.ijpharm.2005.11.014","article-title":"Pharmacokinetic and pharmacodynamic studies following oral administration of erythropoietin mucoadhesive tablets to beagle dogs","volume":"310","author":"Venkatesan","year":"2006","journal-title":"Int J Pharm"},{"issue":"suppl 2","key":"10.1016\/j.pharmr.2026.100155_bib79","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2337\/diacare.5.2.S13","article-title":"Clinical pharmacologic studies with human insulin (recombinant DNA)","volume":"5","author":"Galloway","year":"1982","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100155_bib80","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1517\/17425255.2012.652615","article-title":"Pharmacokinetics of alteplase in the treatment of ischaemic stroke","volume":"8","author":"Acheampong","year":"2012","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100155_bib81","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1111\/j.1747-4949.2012.00924.x","article-title":"The influence of bolus to infusion delays on plasma tissue plasminogen activator levels","volume":"9","author":"Smith","year":"2014","journal-title":"Int J Stroke"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100155_bib82","doi-asserted-by":"crossref","DOI":"10.1515\/jbcpp-2019-0337","article-title":"Intravenous insulin therapy in diabetes mellitus with hyperglycemic crisis and intercurrent illness","volume":"30","author":"Suprapti","year":"2020","journal-title":"J Basic Clin Physiol Pharmacol"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100155_bib83","doi-asserted-by":"crossref","first-page":"96","DOI":"10.6065\/apem.2016.21.2.96","article-title":"Multiple daily injection of insulin regimen for a 10-month-old infant with type 1 diabetes mellitus and diabetic ketoacidosis","volume":"21","author":"Park","year":"2016","journal-title":"Ann Pediatr Endocrinol Metab"},{"key":"10.1016\/j.pharmr.2026.100155_bib84","article-title":"Target-mediated disposition population pharmacokinetics model of erythropoietin in premature neonates following multiple intravenous and subcutaneous dosing regimens","volume":"138","author":"D\u2019Cunha","year":"2019","journal-title":"Eur J Pharm Sci"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100155_bib85","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s13318-024-00889-1","article-title":"A phase I clinical study comparing the pharmacokinetics, safety, and immunogenicity of GB221 injection and trastuzumab (Herceptin\u00ae) in healthy Chinese adults","volume":"49","author":"Zhu","year":"2024","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100155_bib86","doi-asserted-by":"crossref","first-page":"e221","DOI":"10.1016\/j.jemermed.2023.06.004","article-title":"Subcutaneous insulin versus traditional intravenous insulin infusion in treatment of mild to moderate diabetic ketoacidosis","volume":"65","author":"Stuhr","year":"2023","journal-title":"J Emerg Med"},{"issue":"12","key":"10.1016\/j.pharmr.2026.100155_bib87","doi-asserted-by":"crossref","first-page":"744","DOI":"10.5414\/CP201561","article-title":"Erythropoiesis-stimulating agents: switch from intravenous to subcutaneous administration in hemodialyzed patients","volume":"49","author":"Bolasco","year":"2011","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1016\/j.pharmr.2026.100155_bib88","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jconrel.2014.03.011","article-title":"Improving the outcomes of biopharmaceutical delivery via the subcutaneous route by understanding the chemical, physical and physiological properties of the subcutaneous injection site","volume":"182","author":"Kinnunen","year":"2014","journal-title":"J Control Release"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100155_bib89","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/j.xphs.2018.01.007","article-title":"Challenges and opportunities for the subcutaneous delivery of therapeutic proteins","volume":"107","author":"Turner","year":"2018","journal-title":"J Pharm Sci"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100155_bib90","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1124\/dmd.114.059238","article-title":"Subcutaneous absorption of biotherapeutics: knowns and unknowns","volume":"42","author":"Richter","year":"2014","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.pharmr.2026.100155_bib91","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.rmed.2019.05.005","article-title":"Monoclonal antibodies for severe asthma: pharmacokinetic profiles","volume":"153","author":"Matera","year":"2019","journal-title":"Respir Med"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100155_bib92","doi-asserted-by":"crossref","first-page":"57","DOI":"10.2174\/1389203717666160526122421","article-title":"Insulin and Lispro insulin: what is common and different in their behavior?","volume":"18","author":"Selivanova","year":"2017","journal-title":"Curr Protein Pept Sci"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100155_bib93","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/bdd.733","article-title":"Non-linear mixed effect modeling of the time-variant disposition of erythropoietin in anemic cancer patients","volume":"32","author":"Ait-Oudhia","year":"2010","journal-title":"Biopharm Drug Dispos"},{"issue":"12","key":"10.1016\/j.pharmr.2026.100155_bib94","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1007\/s40262-013-0098-x","article-title":"Clinical pharmacokinetics and pharmacodynamics of erythropoiesis-stimulating agents","volume":"52","author":"Doshi","year":"2013","journal-title":"Clin Pharmacokinet"},{"issue":"3-4","key":"10.1016\/j.pharmr.2026.100155_bib95","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.ejps.2005.06.010","article-title":"Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after multiple subcutaneous doses in healthy subjects","volume":"26","author":"Krzyzanski","year":"2005","journal-title":"Eur J Pharm Sci"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100155_bib96","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.clinthera.2014.03.015","article-title":"Safety, tolerability, pharmacokinetics, and pharmacodynamics of recombinant human parathyroid hormone (1-34) in healthy Chinese subjects","volume":"36","author":"Liu","year":"2014","journal-title":"Clin Ther"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100155_bib97","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1055\/s-2003-39506","article-title":"Pharmacokinetic-pharmacodynamic modelling of recombinant human erythropoietin in athletes","volume":"24","author":"Varlet-Marie","year":"2003","journal-title":"Int J Sports Med"},{"key":"10.1016\/j.pharmr.2026.100155_bib98","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2022.106218","article-title":"Pharmacokinetic and pharmacodynamic studies of supaglutide in rats and monkeys","volume":"175","author":"Liao","year":"2022","journal-title":"Eur J Pharm Sci"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100155_bib99","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s40262-025-01578-1","article-title":"Randomized, double-blind, phase I pharmacokinetic study of subcutaneous recombinant human superoxide dismutase (rhSOD) in healthy volunteers","volume":"65","author":"Al Jalali","year":"2026","journal-title":"Clin Pharmacokinet"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100155_bib100","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1111\/jth.15744","article-title":"First randomized evaluation of safety, pharmacodynamics, and pharmacokinetics of BAY 1831865, an antibody targeting coagulation factor XI and factor XIa, in healthy men","volume":"20","author":"Nowotny","year":"2022","journal-title":"J Thromb Haemost"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100155_bib101","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s11095-025-03819-1","article-title":"Pharmacokinetics of nivolumab and erythropoietin in a rat model of diet-induced obesity","volume":"42","author":"Sheng","year":"2025","journal-title":"Pharm Res"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100155_bib102","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1002\/psp4.13166","article-title":"Population pharmacokinetic modeling of sotatercept in healthy participants and patients with pulmonary arterial hypertension","volume":"13","author":"Ait-Oudhia","year":"2024","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1016\/j.pharmr.2026.100155_bib103","article-title":"Pharmacodynamics, pharmacokinetics, and toxicology of Fc-growth hormone fusion protein in macaques","volume":"81","author":"Liu","year":"2025","journal-title":"Growth Horm IGF Res"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100155_bib104","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1111\/j.1749-6632.1994.tb55710.x","article-title":"Pharmacokinetics and application of erythropoietin therapy: overview of epoetin alfa studies in Japan","volume":"718","author":"Shimosaka","year":"1994","journal-title":"Ann N Y Acad Sci"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100155_bib105","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s13238-017-0408-4","article-title":"Pharmacokinetics of monoclonal antibodies and Fc-fusion proteins","volume":"9","author":"Liu","year":"2018","journal-title":"Protein Cell"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100155_bib106","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1080\/10717544.2018.1551442","article-title":"ENHANZE\u00ae drug delivery technology: a novel approach to subcutaneous administration using recombinant human hyaluronidase 20","volume":"26","author":"Locke","year":"2019","journal-title":"Drug Deliv"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100155_bib107","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0254765","article-title":"Dispersive effects and focused biodistribution of recombinant human hyaluronidase PH20: a locally acting and transiently active permeation enhancer","volume":"16","author":"Kang","year":"2021","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100155_bib108","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1002\/cpt.2385","article-title":"Safety, tolerability, and pharmacokinetics of high-volume subcutaneous crenezumab, with and without recombinant human hyaluronidase in healthy volunteers","volume":"110","author":"Dolton","year":"2021","journal-title":"Clin Pharmacol Ther"},{"issue":"13","key":"10.1016\/j.pharmr.2026.100155_bib109","article-title":"Subcutaneous administration of a zwitterionic chitosan-based hydrogel for controlled spatiotemporal release of monoclonal antibodies","volume":"36","author":"Gr\u00e9a","year":"2024","journal-title":"Adv Mater"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100155_bib110","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1124\/dmd.111.043604","article-title":"Lymphatic transport and catabolism of therapeutic proteins after subcutaneous administration to rats and dogs","volume":"40","author":"Wang","year":"2012","journal-title":"Drug Metab Dispos"},{"issue":"2 suppl 1","key":"10.1016\/j.pharmr.2026.100155_bib111","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/0272-6386(93)70178-2","article-title":"Intravenous versus subcutaneous dosing of epoetin: a review of the literature","volume":"22","author":"Ashai","year":"1993","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100155_bib112","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1111\/j.1365-2516.2011.02735.x","article-title":"Intravascular recovery of VWF and FVIII following intraperitoneal injection and differences from intravenous and subcutaneous injection in mice","volume":"18","author":"Shi","year":"2012","journal-title":"Haemophilia"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100155_bib113","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/BF00276825","article-title":"Matched glucose responses to insulin administered subcutaneously and intravenously. Evidence for subcutaneous inactivation of insulin","volume":"18","author":"Stevenson","year":"1980","journal-title":"Diabetologia"},{"key":"10.1016\/j.pharmr.2026.100155_bib114","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.jconrel.2021.06.023","article-title":"Evaluating parameters affecting drug fate at the intramuscular injection site","volume":"336","author":"McCartan","year":"2021","journal-title":"J Control Release"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100155_bib115","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1093\/humrep\/deg446","article-title":"Bioavailability of hCG after intramuscular or subcutaneous injection in obese and non-obese women","volume":"18","author":"Chan","year":"2003","journal-title":"Hum Reprod"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100155_bib116","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S0015-0282(16)54476-8","article-title":"Pharmacodynamics and pharmacokinetics after subcutaneous and intramuscular injection of human chorionic gonadotropin","volume":"56","author":"Saal","year":"1991","journal-title":"Fertil Steril"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100155_bib117","doi-asserted-by":"crossref","first-page":"575","DOI":"10.2337\/diacare.9.6.575","article-title":"Free-insulin profiles after intraperitoneal, intramuscular, and subcutaneous insulin administration","volume":"9","author":"Micossi","year":"1986","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100155_bib118","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/clpt.1984.101","article-title":"Interferon kinetics and adverse reactions after intravenous, intramuscular, and subcutaneous injection","volume":"35","author":"Wills","year":"1984","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100155_bib119","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1046\/j.1468-1331.1998.520187.x","article-title":"Comparative pharmacokinetics and pharmacodynamics of recombinant human interferon beta-1a after intramuscular and subcutaneous administration","volume":"5","author":"Munafo","year":"1998","journal-title":"Eur J Neurol"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100155_bib120","doi-asserted-by":"crossref","first-page":"71","DOI":"10.7748\/ns.2023.e12161","article-title":"Intramuscular injection: exploring the evidence on effective administration","volume":"38","author":"Ogston-Tuck","year":"2023","journal-title":"Nurs Stand"},{"issue":"12","key":"10.1016\/j.pharmr.2026.100155_bib121","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.2337\/diacare.19.12.1434","article-title":"Subcutaneous or intramuscular injections of insulin in children. Are we injecting where we think we are?","volume":"19","author":"Polak","year":"1996","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100155_bib122","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1016\/j.drudis.2022.02.003","article-title":"Emerging trends in pulmonary delivery of biopharmaceuticals","volume":"27","author":"Kunde","year":"2022","journal-title":"Drug Discov Today"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100155_bib123","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/nrd2153","article-title":"Inhaling medicines: delivering drugs to the body through the lungs","volume":"6","author":"Patton","year":"2007","journal-title":"Nat Rev Drug Discov"},{"issue":"1-2","key":"10.1016\/j.pharmr.2026.100155_bib124","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.ijpharm.2013.02.031","article-title":"Inhaled proteins: challenges and perspectives","volume":"447","author":"Depreter","year":"2013","journal-title":"Int J Pharm"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100155_bib125","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1124\/pharmrev.120.000108","article-title":"Inhaled medicines: past, present, and future","volume":"74","author":"Anderson","year":"2022","journal-title":"Pharmacol Rev"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100155_bib126","doi-asserted-by":"crossref","first-page":"239","DOI":"10.2337\/diacare.27.1.239","article-title":"Concept, strategies, and feasibility of noninvasive insulin delivery","volume":"27","author":"Cefalu","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1016\/j.pharmr.2026.100155_bib127","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.ejpb.2021.04.003","article-title":"Oral inhalation for delivery of proteins and peptides to the lungs","volume":"163","author":"Fr\u00f6hlich","year":"2021","journal-title":"Eur J Pharm Biopharm"},{"issue":"suppl 6","key":"10.1016\/j.pharmr.2026.100155_bib128","first-page":"53","article-title":"Systemic treatment by inhalation of macromolecules-principles, problems, and examples","volume":"59","author":"Siekmeier","year":"2008","journal-title":"J Physiol Pharmacol"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100155_bib129","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1007\/s11095-007-9426-x","article-title":"Comparison of albumin uptake in rat alveolar type II and type I-like epithelial cells in primary culture","volume":"25","author":"Ikehata","year":"2007","journal-title":"Pharm Res"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100155_bib130","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1023\/A:1025005232421","article-title":"Transcytosis of GCSF-transferrin across rat alveolar epithelial cell monolayers","volume":"20","author":"Widera","year":"2003","journal-title":"Pharm Res"},{"issue":"26","key":"10.1016\/j.pharmr.2026.100155_bib131","doi-asserted-by":"crossref","first-page":"9763","DOI":"10.1073\/pnas.0403235101","article-title":"Pulmonary delivery of an erythropoietin Fc fusion protein in non-human primates through an immunoglobulin transport pathway","volume":"101","author":"Bitonti","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100155_bib132","article-title":"Pharmacokinetics and pharmacodynamics of inhaled molgramostim in healthy people","volume":"12","author":"Trapnell","year":"2025","journal-title":"BMJ Open Respir Res"},{"issue":"10","key":"10.1016\/j.pharmr.2026.100155_bib133","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00686-25","article-title":"Safety, pharmacokinetics, and pharmacodynamics of human interferon-\u03b12b spray in healthy participants","volume":"69","author":"Zhang","year":"2025","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100155_bib134","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0964-3397(98)80268-1","article-title":"Dornase-alfa (DNase, Pulmozyme) for cystic fibrosis","volume":"14","author":"MacConnachie","year":"1998","journal-title":"Intensive Crit Care Nurs"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100155_bib135","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.2337\/diacare.28.5.1077","article-title":"Time-action profile of inhaled insulin in comparison with subcutaneously injected insulin lispro and regular human insulin","volume":"28","author":"Rave","year":"2005","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100155_bib136","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1586\/14737167.8.1.33","article-title":"Can inhaled insulin be used for the treatment of diabetes mellitus?","volume":"8","author":"de Galan","year":"2008","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100155_bib137","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1177\/1932296816658055","article-title":"Pharmacokinetic and pharmacodynamic properties of a novel inhaled insulin","volume":"11","author":"Heinemann","year":"2016","journal-title":"J Diabetes Sci Technol"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100155_bib138","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1111\/j.1463-1326.2009.01039.x","article-title":"Pharmacokinetics and linear exposure of AFRESA\u2122 compared with the subcutaneous injection of regular human insulin","volume":"11","author":"Rave","year":"2009","journal-title":"Diabetes Obes Metab"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100155_bib139","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1208\/s12249-019-1505-x","article-title":"Caproyl-modified G2 PAMAM dendrimer (G2-AC) nanocomplexes increases the pulmonary absorption of insulin","volume":"20","author":"Yan","year":"2019","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.pharmr.2026.100155_bib140","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jconrel.2017.12.009","article-title":"Fate of pegylated antibody fragments following delivery to the lungs: influence of delivery site, PEG size and lung inflammation","volume":"272","author":"Patil","year":"2018","journal-title":"J Control Release"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100155_bib141","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jconrel.2007.06.017","article-title":"Improvement of pulmonary absorption of insulin and other water-soluble compounds by polyamines in rats","volume":"122","author":"He","year":"2007","journal-title":"J Control Release"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100155_bib142","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/j.xphs.2023.02.010","article-title":"Protein aggregates in inhaled biologics: challenges and considerations","volume":"112","author":"Ibrahim","year":"2023","journal-title":"J Pharm Sci"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100155_bib143","doi-asserted-by":"crossref","first-page":"99","DOI":"10.2165\/00003088-199120020-00002","article-title":"Clinical pharmacokinetics of epoetin (recombinant human erythropoietin)","volume":"20","author":"Macdougall","year":"1991","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100155_bib144","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1208\/s12248-009-9157-5","article-title":"Biodistribution mechanisms of therapeutic monoclonal antibodies in health and disease","volume":"12","author":"Tabrizi","year":"2010","journal-title":"AAPS J"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100155_bib145","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1002\/jps.2600840808","article-title":"Enhanced cellular uptake and in vivo biodistribution of a monoclonal antibody following cationization","volume":"84","author":"Pardridge","year":"1995","journal-title":"J Pharm Sci"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100155_bib146","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1210\/jcem-64-4-657","article-title":"The effect of circulating growth hormone-binding protein on metabolic clearance, distribution, and degradation of human growth hormone","volume":"64","author":"Baumann","year":"1987","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100155_bib147","doi-asserted-by":"crossref","first-page":"8433","DOI":"10.1038\/s41467-025-62955-9","article-title":"Tailored collagen binding of albumin-fused hyperactive coagulation factor IX dictates in vivo distribution and functional properties","volume":"16","author":"Aaen","year":"2025","journal-title":"Nat Commun"},{"issue":"17","key":"10.1016\/j.pharmr.2026.100155_bib148","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1161\/01.CIR.0000163542.48611.A2","article-title":"Tissue-type plasminogen activator crosses the intact blood-brain barrier by low-density lipoprotein receptor-related protein-mediated transcytosis","volume":"111","author":"Benchenane","year":"2005","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100155_bib149","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s12013-012-9477-4","article-title":"Pharmacokinetics, tissue distribution and excretion of recombinant human parathyroid hormone 1-84 in animals","volume":"66","author":"Bai","year":"2013","journal-title":"Cell Biochem Biophys"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100155_bib150","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1023\/B:PHAM.0000048199.94510.b0","article-title":"Pharmacokinetic and biodistribution profile of recombinant human interleukin-10 following intravenous administration in rats with extensive liver fibrosis","volume":"21","author":"Rachmawati","year":"2004","journal-title":"Pharm Res"},{"issue":"13","key":"10.1016\/j.pharmr.2026.100155_bib151","first-page":"3577","article-title":"Differences of biodistribution, pharmacokinetics, and tumor targeting between interleukins 2 and 15","volume":"60","author":"Kobayashi","year":"2000","journal-title":"Cancer Res"},{"issue":"3 suppl 3","key":"10.1016\/j.pharmr.2026.100155_bib152","first-page":"S29","article-title":"Assessments of antibody biodistribution","volume":"55","author":"Glassman","year":"2015","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.pharmr.2026.100155_bib153","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2021.753833","article-title":"The contribution of liver sinusoidal endothelial cells to clearance of therapeutic antibody","volume":"12","author":"James","year":"2022","journal-title":"Front Physiol"},{"issue":"5A","key":"10.1016\/j.pharmr.2026.100155_bib154","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/0002-9343(88)90399-3","article-title":"Hepatic metabolism of insulin","volume":"85","author":"Duckworth","year":"1988","journal-title":"Am J Med"},{"issue":"34","key":"10.1016\/j.pharmr.2026.100155_bib155","doi-asserted-by":"crossref","first-page":"18220","DOI":"10.1016\/S0021-9258(19)81348-0","article-title":"Characterization of the interaction in vivo of tissue-type plasminogen activator with liver cells","volume":"263","author":"Kuiper","year":"1988","journal-title":"J Biol Chem"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100155_bib156","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S0090-9556(25)08718-5","article-title":"Total body and hepatic clearance in rats of recombinant tissue-type plasminogen activator expressed in mouse C127 and Chinese hamster ovary cells","volume":"20","author":"Hori","year":"1992","journal-title":"Drug Metab Dispos"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100155_bib157","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1111\/j.1600-0676.1990.tb00479.x","article-title":"The metabolism of recombinant erythropoietin in the isolated perfused rat liver","volume":"10","author":"Nielsen","year":"1990","journal-title":"Liver"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100155_bib158","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/ki.1990.166","article-title":"Metabolism of parathyroid hormone in isolated perfused rat kidney and liver combined","volume":"38","author":"Daugaard","year":"1990","journal-title":"Kidney Int"},{"issue":"3 suppl","key":"10.1016\/j.pharmr.2026.100155_bib159","first-page":"852s","article-title":"Uptake and metabolism of 111In-labeled monoclonal antibody B6.2 by the rat liver","volume":"50","author":"Jones","year":"1990","journal-title":"Cancer Res"},{"issue":"1 Pt 2","key":"10.1016\/j.pharmr.2026.100155_bib160","first-page":"F168","article-title":"Metabolism of pure human erythropoietin in the rat","volume":"247","author":"Emmanouel","year":"1984","journal-title":"Am J Physiol"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100155_bib161","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1042\/bj2960771","article-title":"Catabolism of hirudin and thrombin-hirudin complexes in the rat","volume":"296","author":"Bichler","year":"1993","journal-title":"Biochem J"},{"issue":"10","key":"10.1016\/j.pharmr.2026.100155_bib162","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1080\/17425255.2019.1678584","article-title":"Pharmacokinetics and pharmacodynamics of pegylated interferon for the treatment of hepatitis B","volume":"15","author":"Yeh","year":"2019","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100155_bib163","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/S0090-9556(25)08086-9","article-title":"Influence of hepatic and renal failure on pharmacokinetic properties of the novel recombinant plasminogen activator BM 06.022 in rats","volume":"21","author":"Martin","year":"1993","journal-title":"Drug Metab Dispos"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100155_bib164","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1159\/000217617","article-title":"Role of the kidney in metabolic change of interleukin-2","volume":"10","author":"Ohnishi","year":"1989","journal-title":"Tumour Biol"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100155_bib165","first-page":"1107","article-title":"Prolongation of serum half-life of interleukin 2 and augmentation of lymphokine-activated killer cell activity by pepstatin in mice","volume":"50","author":"Ohnishi","year":"1990","journal-title":"Cancer Res"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100155_bib166","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1038\/sj.clpt.6100165","article-title":"Change in erythropoietin pharmacokinetics following hematopoietic transplantation","volume":"81","author":"Widness","year":"2007","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100155_bib167","first-page":"608","article-title":"Insulin degradation: progress and potential","volume":"19","author":"Duckworth","year":"1998","journal-title":"Endocr Rev"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100155_bib168","doi-asserted-by":"crossref","DOI":"10.1016\/j.jmb.2022.167458","article-title":"Structural investigations of full-length insulin receptor dynamics and signalling","volume":"434","author":"Nielsen","year":"2022","journal-title":"J Mol Biol"},{"issue":"7431","key":"10.1016\/j.pharmr.2026.100155_bib169","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/nature11781","article-title":"How insulin engages its primary binding site on the insulin receptor","volume":"493","author":"Menting","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.pharmr.2026.100155_bib170","series-title":"Hormone Receptors: Structures and Functions","first-page":"151","article-title":"The three-dimensional structure of insulin and its receptor","author":"Forbes","year":"2023"},{"issue":"20","key":"10.1016\/j.pharmr.2026.100155_bib171","doi-asserted-by":"crossref","first-page":"5007","DOI":"10.3390\/ijms20205007","article-title":"Insulin receptor trafficking: consequences for insulin sensitivity and diabetes","volume":"20","author":"Chen","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100155_bib172","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1210\/endo-104-6-1758","article-title":"Insulin degradation by liver cell membranes","volume":"104","author":"Duckworth","year":"1979","journal-title":"Endocrinology"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100155_bib173","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.3390\/ijms22052235","article-title":"Targeting insulin-degrading enzyme in insulin clearance","volume":"22","author":"Leissring","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100155_bib174","doi-asserted-by":"crossref","first-page":"9437","DOI":"10.1074\/jbc.M110188200","article-title":"Endosomal proteolysis of internalized insulin at the C-terminal region of the B chain by cathepsin D","volume":"277","author":"Authier","year":"2002","journal-title":"J Biol Chem"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100155_bib175","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1210\/edrv-9-3-319","article-title":"Insulin degradation: mechanisms, products, and significance","volume":"9","author":"Duckworth","year":"1988","journal-title":"Endocr Rev"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100155_bib176","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1080\/10409238.2017.1337707","article-title":"Multiple functions of insulin-degrading enzyme: a metabolic crosslight?","volume":"52","author":"Tundo","year":"2017","journal-title":"Crit Rev Biochem Mol Biol"},{"issue":"12","key":"10.1016\/j.pharmr.2026.100155_bib177","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1007\/s00125-009-1551-0","article-title":"Endosomal proteolysis of internalised [ArgA0]-human insulin at neutral pH generates the mature insulin peptide in rat liver in vivo","volume":"52","author":"Kouach","year":"2009","journal-title":"Diabetologia"},{"issue":"10","key":"10.1016\/j.pharmr.2026.100155_bib178","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1681\/ASN.V9101759","article-title":"Megalin is an endocytic receptor for insulin","volume":"9","author":"Orlando","year":"1998","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.pharmr.2026.100155_bib179","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/bs.vh.2017.02.005","article-title":"Erythropoietin receptor structural domains","volume":"105","author":"Li","year":"2017","journal-title":"Vitam Horm"},{"issue":"9","key":"10.1016\/j.pharmr.2026.100155_bib180","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.4103\/1673-5374.215240","article-title":"Neuroprotective effects of erythropoietin on neurodegenerative and ischemic brain diseases: the role of erythropoietin receptor","volume":"12","author":"Hern\u00e1ndez","year":"2017","journal-title":"Neural Regen Res"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100155_bib181","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1182\/blood-2004-03-1216","article-title":"Both proteasomes and lysosomes degrade the activated erythropoietin receptor","volume":"105","author":"Walrafen","year":"2005","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100155_bib182","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.1002\/jps.21578","article-title":"Investigation of the effects of altered receptor binding activity on the clearance of erythropoiesis-stimulating proteins: nonerythropoietin receptor-mediated pathways may play a major role","volume":"98","author":"Agoram","year":"2009","journal-title":"J Pharm Sci"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100155_bib183","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1007\/s12185-010-0496-x","article-title":"Glycosylation-modified erythropoietin with improved half-life and biological activity","volume":"91","author":"Su","year":"2010","journal-title":"Int J Hematol"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100155_bib184","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1161\/STROKEAHA.114.007143","article-title":"Impact of alcohol consumption on the outcome of ischemic stroke and thrombolysis: role of the hepatic clearance of tissue-type plasminogen activator","volume":"46","author":"Lemarchand","year":"2015","journal-title":"Stroke"},{"issue":"suppl 2","key":"10.1016\/j.pharmr.2026.100155_bib185","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/0049-3848(90)90379-Q","article-title":"Receptor-mediated endocytosis of tissue-type plasminogen activator (t-PA) by liver cells","volume":"57","author":"Rijken","year":"1990","journal-title":"Thromb Res"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100155_bib186","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S0731-7085(01)00431-9","article-title":"Pharmacokinetic studies of Gln117 tissue-type plasminogen activator in rats","volume":"26","author":"Aoki","year":"2001","journal-title":"J Pharm Biomed Anal"},{"issue":"16","key":"10.1016\/j.pharmr.2026.100155_bib187","doi-asserted-by":"crossref","first-page":"7422","DOI":"10.1073\/pnas.89.16.7422","article-title":"Complexes of tissue-type plasminogen activator and its serpin inhibitor plasminogen-activator inhibitor type 1 are internalized by means of the low density lipoprotein receptor-related protein\/alpha 2-macroglobulin receptor","volume":"89","author":"Orth","year":"1992","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100155_bib188","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1042\/bj2820841","article-title":"Endocytosis and intracellular processing of tissue-type plasminogen activator by rat liver cells in vivo","volume":"282","author":"Stang","year":"1992","journal-title":"Biochem J"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100155_bib189","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1136\/svn-2023-002883","article-title":"Anti-stroke biologics: from recombinant proteins to stem cells and organoids","volume":"9","author":"Miao","year":"2024","journal-title":"Stroke Vasc Neurol"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100155_bib190","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1042\/bj2380643","article-title":"Clearance of the heavy and light polypeptide chains of human tissue-type plasminogen activator in rats","volume":"238","author":"Rijken","year":"1986","journal-title":"Biochem J"},{"issue":"19","key":"10.1016\/j.pharmr.2026.100155_bib191","doi-asserted-by":"crossref","first-page":"5997","DOI":"10.1073\/pnas.1408766112","article-title":"Charge-mediated influence of the antibody variable domain on FcRn-dependent pharmacokinetics","volume":"112","author":"Schoch","year":"2015","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100155_bib192","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1385\/IR:25:2:097","article-title":"Transcytosis and catabolism of antibody","volume":"25","author":"Ghetie","year":"2002","journal-title":"Immunol Res"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100155_bib193","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1002\/jps.24444","article-title":"Antibody glycosylation and its impact on the pharmacokinetics and pharmacodynamics of monoclonal antibodies and Fc-fusion proteins","volume":"104","author":"Liu","year":"2015","journal-title":"J Pharm Sci"},{"issue":"9","key":"10.1016\/j.pharmr.2026.100155_bib194","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/nri2155","article-title":"FcRn: the neonatal Fc receptor comes of age","volume":"7","author":"Roopenian","year":"2007","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.pharmr.2026.100155_bib195","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.ijbiomac.2018.07.141","article-title":"Boosting half-life and effector functions of therapeutic antibodies by Fc-engineering: an interaction-function review","volume":"119","author":"Fonseca","year":"2018","journal-title":"Int J Biol Macromol"},{"key":"10.1016\/j.pharmr.2026.100155_bib196","doi-asserted-by":"crossref","first-page":"580","DOI":"10.3389\/fimmu.2016.00580","article-title":"Advances in therapeutic Fc engineering\u2014modulation of igG-associated effector functions and serum half-life","volume":"7","author":"Saxena","year":"2016","journal-title":"Front Immunol"},{"key":"10.1016\/j.pharmr.2026.100155_bib197","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1283120","article-title":"Fc-mediated functions of nirsevimab complement direct respiratory syncytial virus neutralization but are not required for optimal prophylactic protection","volume":"14","author":"Brady","year":"2023","journal-title":"Front Immunol"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100155_bib198","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1124\/dmd.121.000799","article-title":"Target-mediated drug disposition affects the pharmacokinetics of interleukin-10 fragment crystallizable fusion proteins at pharmacologically active doses","volume":"50","author":"Yang","year":"2022","journal-title":"Drug Metab Dispos"},{"issue":"1-2","key":"10.1016\/j.pharmr.2026.100155_bib199","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S1359-6446(05)03638-X","article-title":"Elimination mechanisms of therapeutic monoclonal antibodies","volume":"11","author":"Tabrizi","year":"2006","journal-title":"Drug Discov Today"},{"issue":"suppl 1","key":"10.1016\/j.pharmr.2026.100155_bib200","article-title":"Clearance function of scavenger endothelial cells","volume":"3","author":"Smedsr\u00f8d","year":"2004","journal-title":"Comp Hepatol"},{"issue":"1-2","key":"10.1016\/j.pharmr.2026.100155_bib201","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.ijpharm.2013.01.001","article-title":"Application of knockout mouse models to investigate the influence of Fc\u03b3R on the pharmacokinetics and anti-platelet effects of MWReg30, a monoclonal anti-GPIIb antibody","volume":"444","author":"Abuqayyas","year":"2013","journal-title":"Int J Pharm"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100155_bib202","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1358\/mf.2004.26.2.800065","article-title":"Factors affecting pharmacokinetics of monoclonal antibodies: a review article","volume":"26","author":"Iznaga-Escobar","year":"2004","journal-title":"Methods Find Exp Clin Pharmacol"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100155_bib203","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.tips.2009.04.007","article-title":"Recombinant antibody therapeutics: the impact of glycosylation on mechanisms of action","volume":"30","author":"Jefferis","year":"2009","journal-title":"Trends Pharmacol Sci"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100155_bib204","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.4049\/jimmunol.143.8.2595","article-title":"Studies of aglycosylated chimeric mouse-human IgG. Role of carbohydrate in the structure and effector functions mediated by the human IgG constant region","volume":"143","author":"Tao","year":"1989","journal-title":"J Immunol"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100155_bib205","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2024.2400414","article-title":"Decoding the mannose receptor-mAb interaction: the importance of high-mannose N-glycans and glycan-pairing","volume":"16","author":"Baumeister","year":"2024","journal-title":"mAbs"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100155_bib206","doi-asserted-by":"crossref","first-page":"475","DOI":"10.4161\/mabs.20737","article-title":"Production, characterization and pharmacokinetic properties of antibodies with N-linked Mannose-5 glycans","volume":"4","author":"Yu","year":"2012","journal-title":"mAbs"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100155_bib207","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1093\/glycob\/cwl057","article-title":"Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and complex types","volume":"17","author":"Kanda","year":"2007","journal-title":"Glycobiology"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100155_bib208","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/S0022-3565(25)20973-9","article-title":"Soluble cytokine receptors as carrier proteins: effects of soluble interleukin-4 receptors on the pharmacokinetics of murine interleukin-4","volume":"279","author":"Ma","year":"1996","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100155_bib209","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/2050-6511-15-7","article-title":"Preclinical and clinical phase I studies of a new recombinant filgrastim (BK0023) in comparison with Neupogen\u00ae","volume":"15","author":"Crobu","year":"2014","journal-title":"BMC Pharmacol Toxicol"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100155_bib210","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/S0022-3565(24)37074-0","article-title":"Mechanism for the nonlinear pharmacokinetics of erythropoietin in rats","volume":"283","author":"Kato","year":"1997","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100155_bib211","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1016\/S0022-3565(25)09527-8","article-title":"Saturable uptake of a recombinant human granulocyte colony-stimulating factor derivative, nartograstim, by the bone marrow and spleen of rats in vivo","volume":"273","author":"Kuwabara","year":"1995","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100155_bib212","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/S0022-3565(25)12681-5","article-title":"Nonlinear pharmacokinetics of tissue-type plasminogen activator in three animal species and isolated perfused rat liver","volume":"255","author":"Tanswell","year":"1990","journal-title":"J Pharmacol Exp Ther"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100155_bib213","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1111\/bph.13473","article-title":"Translational mixed-effects PKPD modelling of recombinant human growth hormone\u2014from hypophysectomized rat to patients","volume":"173","author":"Thorsted","year":"2016","journal-title":"Br J Pharmacol"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100155_bib214","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1093\/jnci\/86.1.39","article-title":"Phase I trial of recombinant human macrophage colony-stimulating factor administered by continuous intravenous infusion in patients with metastatic cancer","volume":"86","author":"Cole","year":"1994","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100155_bib215","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0928-0987(00)00219-0","article-title":"Estimation of rhG-CSF absorption kinetics after subcutaneous administration using a modified Wagner-Nelson method with a nonlinear elimination model","volume":"13","author":"Hayashi","year":"2001","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.pharmr.2026.100155_bib216","doi-asserted-by":"crossref","DOI":"10.1016\/j.vascn.2024.107541","article-title":"Nonclinical pharmacokinetics of E3112, a recombinant human hepatocyte growth factor, in rats and monkeys by a simple ELISA kit assay","volume":"128","author":"Aoyama","year":"2024","journal-title":"J Pharmacol Toxicol Methods"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100155_bib217","doi-asserted-by":"crossref","first-page":"3292","DOI":"10.1111\/bcp.14750","article-title":"Pharmacokinetics and safety of pegylated recombinant human granulocyte colony-stimulating factor in children with acute leukaemia","volume":"87","author":"Liu","year":"2021","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100155_bib218","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.70109","article-title":"Population pharmacokinetics-pharmacodynamics and exposure-response of ropeginterferon Alfa-2b in Chinese and Japanese patients with polycythemia Vera","volume":"13","author":"Qin","year":"2025","journal-title":"Pharmacol Res Perspect"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100155_bib219","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1002\/jcp.1041530323","article-title":"Nonreceptor mediated nuclear accumulation of insulin in H35 rat hepatoma cells","volume":"153","author":"Harada","year":"1992","journal-title":"J Cell Physiol"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100155_bib220","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/0020-711X(85)90268-X","article-title":"Degradation of insulin by human fibroblasts: effects of inhibitors of pinocytosis and lysosomal activity","volume":"17","author":"Kooistra","year":"1985","journal-title":"Int J Biochem"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100155_bib221","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2022.2085535","article-title":"Effect of molecular size on interstitial pharmacokinetics and tissue catabolism of antibodies","volume":"14","author":"Rafidi","year":"2022","journal-title":"mAbs"},{"key":"10.1016\/j.pharmr.2026.100155_bib222","doi-asserted-by":"crossref","DOI":"10.1016\/j.taap.2021.115796","article-title":"Non-clinical safety assessment and in vivo biodistribution of CoviFab, an RBD-specific F(ab\u2032)2 fragment derived from equine polyclonal antibodies","volume":"434","author":"Salinas","year":"2022","journal-title":"Toxicol Appl Pharmacol"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100155_bib223","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.xphs.2015.11.015","article-title":"PEGylation of biopharmaceuticals: a review of chemistry and nonclinical safety information of approved drugs","volume":"105","author":"Turecek","year":"2016","journal-title":"J Pharm Sci"},{"issue":"12","key":"10.1016\/j.pharmr.2026.100155_bib224","doi-asserted-by":"crossref","first-page":"4414","DOI":"10.1002\/jps.23320","article-title":"The impact of sialic acids on the pharmacokinetics of a pegylated erythropoietin","volume":"101","author":"Liu","year":"2012","journal-title":"J Pharm Sci"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100155_bib225","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.jconrel.2010.07.127","article-title":"An ultrasound-responsive nano delivery system of tissue-type plasminogen activator for thrombolytic therapy","volume":"147","author":"Uesugi","year":"2010","journal-title":"J Control Release"},{"issue":"21","key":"10.1016\/j.pharmr.2026.100155_bib226","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1016\/S1359-6446(05)03575-0","article-title":"PEGylation, successful approach to drug delivery","volume":"10","author":"Veronese","year":"2005","journal-title":"Drug Discov Today"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100155_bib227","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1007\/s12185-016-2000-8","article-title":"Epoetin beta pegol, but not recombinant erythropoietin, retains its hematopoietic effect in vivo in the presence of the sialic acid-metabolizing enzyme sialidase","volume":"104","author":"Aizawa","year":"2016","journal-title":"Int J Hematol"},{"issue":"9","key":"10.1016\/j.pharmr.2026.100155_bib228","doi-asserted-by":"crossref","DOI":"10.1002\/pro.4727","article-title":"Growth hormone receptor agonists and antagonists: from protein expression and purification to long-acting formulations","volume":"32","author":"Wang","year":"2023","journal-title":"Protein Sci"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100155_bib229","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s10930-017-9699-9","article-title":"Molecular design, expression and evaluation of PASylated human recombinant erythropoietin with enhanced functional properties","volume":"36","author":"Hedayati","year":"2017","journal-title":"Protein J"},{"issue":"24","key":"10.1016\/j.pharmr.2026.100155_bib230","first-page":"6964","article-title":"Genetically engineered tetravalent single-chain Fv of the pancarcinoma monoclonal antibody CC49: improved biodistribution and potential for therapeutic application","volume":"60","author":"Goel","year":"2000","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100155_bib231","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s40272-021-00478-8","article-title":"Lonapegsomatropin: Pediatric first approval","volume":"24","author":"Lamb","year":"2022","journal-title":"Paediatr Drugs"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100155_bib232","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/s41574-024-01075-8","article-title":"Hypoparathyroidism: diagnosis, management and emerging therapies","volume":"21","author":"Khan","year":"2025","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.pharmr.2026.100155_bib233","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.jconrel.2025.01.035","article-title":"Albumin-based delivery systems: recent advances, challenges, and opportunities","volume":"380","author":"Murphy","year":"2025","journal-title":"J Control Release"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100155_bib234","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1517\/17425247.2015.993313","article-title":"Albumin and its application in drug delivery","volume":"12","author":"Sleep","year":"2015","journal-title":"Expert Opin Drug Deliv"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100155_bib235","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1556\/1886.2024.00045","article-title":"Preclinical assessment of a recombinant RBD-Fc fusion protein as SARS-CoV-2 candidate vaccine","volume":"14","author":"Dashti","year":"2024","journal-title":"Eur J Microbiol Immunol (Bp)"},{"key":"10.1016\/j.pharmr.2026.100155_bib236","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.116485","article-title":"The effects of Fc fusion protein glucagon-like peptide-1 and glucagon dual receptor agonist with different receptor selectivity in vivo studies","volume":"174","author":"Jiang","year":"2024","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.pharmr.2026.100155_bib237","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.jconrel.2024.08.022","article-title":"Transplacental delivery of factor IX Fc-fusion protein ameliorates bleeding phenotype of newborn hemophilia B mice","volume":"374","author":"Sakurai","year":"2024","journal-title":"J Control Release"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100155_bib238","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-011789","article-title":"Engineered IL-18 variants with half-life extension and improved stability for cancer immunotherapy","volume":"13","author":"Bainbridge","year":"2025","journal-title":"J Immunother Cancer"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100155_bib239","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1080\/13543784.2025.2500303","article-title":"A phase 1, randomized, double-blind, placebo-controlled trial investigating the safety, tolerability, pharmacokinetics, and pharmacodynamics of KN056 (a recombinant human GLP-1 variant Fc fusion protein) in healthy Chinese participants","volume":"34","author":"Qin","year":"2025","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.pharmr.2026.100155_bib240","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2025.105822","article-title":"Effectorless Fc-fusion improves FLT3L drug-like properties for cancer immunotherapy combinations","volume":"118","author":"Decalf","year":"2025","journal-title":"EBiomedicine"},{"issue":"9","key":"10.1016\/j.pharmr.2026.100155_bib241","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1002\/cpdd.1091","article-title":"Comparative pharmacokinetics, safety, and immunogenicity study of the prefilled syringe and lyophilized formulation of a recombinant human tumor necrosis factor-\u03b1 receptor II: lgG Fc fusion protein in healthy Chinese male subjects","volume":"11","author":"Huang","year":"2022","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100155_bib242","doi-asserted-by":"crossref","DOI":"10.1111\/cts.70055","article-title":"A first-in-human, randomized study of the safety, pharmacokinetics and pharmacodynamics of povetacicept, an enhanced dual BAFF\/APRIL antagonist, in healthy adults","volume":"17","author":"Davies","year":"2024","journal-title":"Clin Transl Sci"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100155_bib243","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s40265-016-0679-8","article-title":"Coagulation factor IX (recombinant), albumin fusion protein (albutrepenonacog alfa; Idelvion\u00ae): a review of its use in haemophilia B","volume":"77","author":"Lyseng-Williamson","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.pharmr.2026.100155_bib244","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.2147\/DDDT.S236788","article-title":"Albumin-fusion recombinant FIX in the management of people with hemophilia B: an evidence-based review","volume":"16","author":"Pasca","year":"2022","journal-title":"Drug Des Dev Ther"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100155_bib245","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/bjh.17559","article-title":"Fusion of engineered albumin with factor IX Padua extends half-life and improves coagulant activity","volume":"194","author":"Lombardi","year":"2021","journal-title":"Br J Haematol"},{"issue":"565","key":"10.1016\/j.pharmr.2026.100155_bib246","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abb0580","article-title":"An engineered human albumin enhances half-life and transmucosal delivery when fused to protein-based biologics","volume":"12","author":"Bern","year":"2020","journal-title":"Sci Transl Med"},{"issue":"17","key":"10.1016\/j.pharmr.2026.100155_bib247","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1007\/s40265-021-01615-w","article-title":"Efmoroctocog alfa: a review in haemophilia A","volume":"81","author":"Frampton","year":"2021","journal-title":"Drugs"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100155_bib248","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1111\/hae.14797","article-title":"Real-world evidence on efmoroctocog alfa in patients with haemophilia A: a systematic literature review of treatment experience in Europe","volume":"29","author":"Blatn\u00fd","year":"2023","journal-title":"Haemophilia"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100155_bib249","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1007\/s40265-023-01866-9","article-title":"Efanesoctocog alfa: first approval","volume":"83","author":"Keam","year":"2023","journal-title":"Drugs"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100155_bib250","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1080\/17474086.2023.2223925","article-title":"Efanesoctocog alfa for the prevention and treatment of bleeding in patients with hemophilia A","volume":"16","author":"Konkle","year":"2023","journal-title":"Expert Rev Hematol"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100155_bib251","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa2312611","article-title":"Efanesoctocog alfa prophylaxis for children with severe hemophilia A","volume":"391","author":"Malec","year":"2024","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100155_bib252","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1056\/NEJMoa2209226","article-title":"Efanesoctocog alfa prophylaxis for patients with severe hemophilia A","volume":"388","author":"von Drygalski","year":"2023","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100155_bib253","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.3324\/haematol.2023.284498","article-title":"Efanesoctocog alfa: the renaissance of factor VIII replacement therapy","volume":"109","author":"Dargaud","year":"2024","journal-title":"Haematologica"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100155_bib254","first-page":"2786","article-title":"First-in-human pharmacokinetic, safety, and preliminary efficacy studies of single- and multiple-dose FRSW117, a novel pegylated recombinant factor VIII-Fc fusion protein with an extended half-life, in patients with severe hemophilia A","volume":"110","author":"Xue","year":"2025","journal-title":"Haematologica"},{"issue":"1 suppl 1","key":"10.1016\/j.pharmr.2026.100155_bib255","first-page":"S33","article-title":"Basal insulin treatment in type 2 diabetes","volume":"13","author":"Hedrington","year":"2011","journal-title":"Diabetes Technol Ther"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100155_bib256","doi-asserted-by":"crossref","first-page":"331","DOI":"10.2165\/00003088-200544040-00001","article-title":"Pharmacokinetic and pharmacodynamic considerations in the development of therapeutic proteins","volume":"44","author":"Mahmood","year":"2005","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100155_bib257","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2021.1993769","article-title":"Effect of variable domain charge on in vitro and in vivo disposition of monoclonal antibodies","volume":"13","author":"Liu","year":"2021","journal-title":"mAbs"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100155_bib258","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s10928-023-09899-z","article-title":"A minimal physiologically based pharmacokinetic model to study the combined effect of antibody size, charge, and binding affinity to FcRn\/antigen on antibody pharmacokinetics","volume":"51","author":"Patidar","year":"2024","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100155_bib259","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1208\/s12248-023-00812-7","article-title":"Physiologically based pharmacokinetic modeling to characterize the effect of molecular charge on whole-body disposition of monoclonal antibodies","volume":"25","author":"Liu","year":"2023","journal-title":"AAPS J"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100155_bib260","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2023.2232087","article-title":"Improved antibody pharmacokinetics by disruption of contiguous positive surface potential and charge reduction using alternate human framework","volume":"15","author":"Ollier","year":"2023","journal-title":"mAbs"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100155_bib261","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1007\/s11095-022-03236-8","article-title":"A charge variant of bevacizumab offers enhanced FcRn-dependent pharmacokinetic half-life and efficacy","volume":"39","author":"Singh","year":"2022","journal-title":"Pharm Res"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100155_bib262","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/j.1527-3466.2004.tb00149.x","article-title":"Therapeutic potential of monteplase in acute myocardial infarction as a powerful thrombolytic agent for pretreatment of coronary intervention","volume":"22","author":"Inoue","year":"2004","journal-title":"Cardiovasc Drug Rev"},{"issue":"9","key":"10.1016\/j.pharmr.2026.100155_bib263","doi-asserted-by":"crossref","first-page":"3670","DOI":"10.1073\/pnas.91.9.3670","article-title":"A faster-acting and more potent form of tissue plasminogen activator","volume":"91","author":"Keyt","year":"1994","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100155_bib264","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1161\/01.CIR.95.2.351","article-title":"TNK-tissue plasminogen activator in acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) 10A dose-ranging trial","volume":"95","author":"Cannon","year":"1997","journal-title":"Circulation"},{"issue":"24","key":"10.1016\/j.pharmr.2026.100155_bib265","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1056\/NEJMoa2400314","article-title":"Reteplase versus alteplase for acute ischemic stroke","volume":"390","author":"Li","year":"2024","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100155_bib266","doi-asserted-by":"crossref","first-page":"445","DOI":"10.2165\/00003088-200241060-00005","article-title":"Comparison of pharmacokinetics of lanoteplase and alteplase during acute myocardial infarction","volume":"41","author":"Kostis","year":"2002","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100155_bib267","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S0049-3848(00)00414-X","article-title":"Pharmacokinetic properties of a novel tissue-type plasminogen activator pamiteplase after single intravenous administration to rats, dogs, and monkeys","volume":"101","author":"Oikawa","year":"2001","journal-title":"Thromb Res"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100155_bib268","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1179\/016164103101201887","article-title":"Reduction of infarction volume by bolus injection of pamiteplase, a modified tissue plasminogen activator with a longer half-life","volume":"25","author":"Suzuki","year":"2003","journal-title":"Neurol Res"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100155_bib269","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1055\/s-0038-1650619","article-title":"A pilot study on bolus administration of recombinant staphylokinase for coronary artery thrombolysis","volume":"76","author":"Vanderschueren","year":"1996","journal-title":"Thromb Haemost"},{"issue":"9","key":"10.1016\/j.pharmr.2026.100155_bib270","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S1474-4422(21)00210-6","article-title":"Non-immunogenic recombinant staphylokinase versus alteplase for patients with acute ischaemic stroke 4\u00b75 h after symptom onset in Russia (FRIDA): a randomised, open label, multicentre, parallel-group, non-inferiority trial","volume":"20","author":"Gusev","year":"2021","journal-title":"Lancet Neurol"},{"issue":"10","key":"10.1016\/j.pharmr.2026.100155_bib271","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S1474-4422(17)30253-3","article-title":"Tenecteplase versus alteplase for management of acute ischaemic stroke (NOR-TEST): a phase 3, randomised, open-label, blinded endpoint trial","volume":"16","author":"Logallo","year":"2017","journal-title":"Lancet Neurol"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100155_bib272","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S1474-4422(22)00124-7","article-title":"Tenecteplase versus alteplase for the management of acute ischaemic stroke in Norway (NOR-TEST 2, part A): a phase 3, randomised, open-label, blinded endpoint, non-inferiority trial","volume":"21","author":"Kvistad","year":"2022","journal-title":"Lancet Neurol"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100155_bib273","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/S0002-9343(00)00380-6","article-title":"Third-generation thrombolytic drugs","volume":"109","author":"Verstraete","year":"2000","journal-title":"Am J Med"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100155_bib274","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1161\/01.CIR.94.2.197","article-title":"Recombinant staphylokinase variants with altered immunoreactivity. I: Construction and characterization","volume":"94","author":"Collen","year":"1996","journal-title":"Circulation"},{"issue":"9","key":"10.1016\/j.pharmr.2026.100155_bib275","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.3390\/biom12091313","article-title":"Glycosylation-the most diverse post-translational modification","volume":"12","author":"Staudacher","year":"2022","journal-title":"Biomolecules"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100155_bib276","doi-asserted-by":"crossref","DOI":"10.1038\/s41581-024-00923-0","article-title":"Publisher Correction: Glycosylation in health and disease","volume":"21","author":"Reily","year":"2025","journal-title":"Nat Rev Nephrol"},{"issue":"10","key":"10.1016\/j.pharmr.2026.100155_bib277","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1038\/nbt1252","article-title":"Post-translational modifications in the context of therapeutic proteins","volume":"24","author":"Walsh","year":"2006","journal-title":"Nat Biotechnol"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100155_bib278","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/s41569-024-00998-z","article-title":"Protein glycosylation in cardiovascular health and disease","volume":"21","author":"Chatham","year":"2024","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.pharmr.2026.100155_bib279","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/s41392-024-01886-1","article-title":"Glycosylation: mechanisms, biological functions and clinical implications","volume":"9","author":"He","year":"2024","journal-title":"Signal Transduct Target Ther"},{"issue":"6722","key":"10.1016\/j.pharmr.2026.100155_bib280","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1126\/science.adp7201","article-title":"Regulated N-glycosylation controls chaperone function and receptor trafficking","volume":"386","author":"Ma","year":"2024","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100155_bib281","doi-asserted-by":"crossref","DOI":"10.1093\/glycob\/cwae002","article-title":"The impact of glycosylation on the structure, function, and interactions of CD14","volume":"34","author":"Quintana","year":"2024","journal-title":"Glycobiology"},{"issue":"24","key":"10.1016\/j.pharmr.2026.100155_bib282","doi-asserted-by":"crossref","first-page":"8859","DOI":"10.3390\/molecules27248859","article-title":"Impact of N-Linked glycosylation on therapeutic proteins","volume":"27","author":"Chen","year":"2022","journal-title":"Molecules"},{"issue":"10","key":"10.1016\/j.pharmr.2026.100155_bib283","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20220094","article-title":"O-glycosylation and its role in therapeutic proteins","volume":"42","author":"Thompson","year":"2022","journal-title":"Biosci Rep"},{"key":"10.1016\/j.pharmr.2026.100155_bib284","first-page":"3","article-title":"N-glycosylation","volume":"1325","author":"Hirata","year":"2021"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100155_bib285","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1021\/acschembio.7b00794","article-title":"Chemically precise glycoengineering improves human insulin","volume":"13","author":"Guan","year":"2017","journal-title":"ACS Chem Biol"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100155_bib286","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1021\/jacs.9b11424","article-title":"Total chemical synthesis of a nonfibrillating human glycoinsulin","volume":"142","author":"Hossain","year":"2020","journal-title":"J Am Chem Soc"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100155_bib287","doi-asserted-by":"crossref","first-page":"369","DOI":"10.23876\/j.krcp.23.074","article-title":"Efficacy and cost-effectiveness of darbepoetin alfa once every 4 weeks versus continuous erythropoietin receptor activator once every 4 weeks for anemia correction in patients with chronic kidney disease not on dialysis","volume":"43","author":"Park","year":"2024","journal-title":"Kidney Res Clin Pract"},{"key":"10.1016\/j.pharmr.2026.100155_bib288","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2025.116944","article-title":"A novel long-acting recombinant follicle-stimulating hormone with hyperglycosylation exhibits improved pharmacokinetic and bioactivity on promoting follicle growth","volume":"237","author":"Sun","year":"2025","journal-title":"Biochem Pharmacol"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100155_bib289","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.3390\/ijms26062672","article-title":"A novel recombinant human FGF21 analog with high glycosylation has a prolonged half-life and affects glycemic and body weight control","volume":"26","author":"Du","year":"2025","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100155_bib290","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2165\/11530550-000000000-00000","article-title":"Glycosylation of therapeutic proteins: an effective strategy to optimize efficacy","volume":"24","author":"Sol\u00e1","year":"2010","journal-title":"BioDrugs"},{"issue":"suppl 3","key":"10.1016\/j.pharmr.2026.100155_bib291","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/ndt\/16.suppl_3.3","article-title":"Development and characterization of novel erythropoiesis stimulating protein (NESP)","volume":"16","author":"Egrie","year":"2001","journal-title":"Nephrol Dial Transplant"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100155_bib292","doi-asserted-by":"crossref","first-page":"499","DOI":"10.2165\/00003495-200464050-00004","article-title":"Differentiating factors between erythropoiesis-stimulating agents: a guide to selection for anaemia of chronic kidney disease","volume":"64","author":"Deicher","year":"2004","journal-title":"Drugs"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100155_bib293","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s11095-012-0921-3","article-title":"The impact of glycosylation on the pharmacokinetics of a TNFR2:Fc fusion protein expressed in Glycoengineered Pichia Pastoris","volume":"30","author":"Liu","year":"2013","journal-title":"Pharm Res"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100155_bib294","first-page":"1975","article-title":"Sialic acid mediated endothelial and hepatic uptake: a mechanism based mathematic model elucidating the complex pharmacokinetics and pharmacodynamics of efmarodocokin alfa, a variably glycosylated fusion protein","volume":"113","author":"Tao","year":"2024","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.pharmr.2026.100155_bib295","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jbiotec.2016.01.018","article-title":"Improvement of in vitro stability and pharmacokinetics of hIFN-\u03b1 by fusing the carboxyl-terminal peptide of hCG \u03b2-subunit","volume":"221","author":"Ceaglio","year":"2016","journal-title":"J Biotechnol"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100155_bib296","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.xphs.2019.05.036","article-title":"Aggregate forms of recombinant human erythropoietin with different charge profile substantially impact biological activities","volume":"109","author":"Ghezlou","year":"2020","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.pharmr.2026.100155_bib297","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.114757","article-title":"Enhancing pharmacokinetic and pharmacodynamic properties of recombinant therapeutic proteins by manipulation of sialic acid content","volume":"163","author":"Chia","year":"2023","journal-title":"Biomed Pharmacother"},{"issue":"23","key":"10.1016\/j.pharmr.2026.100155_bib298","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1182\/blood.2024027038","article-title":"Enhanced \u03b12-3-linked sialylation determines the extended half-life of CHO-rVWF","volume":"145","author":"Byrne","year":"2025","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100155_bib299","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1007\/s12033-012-9531-x","article-title":"Generation and comparative characterization of glycosylated and aglycosylated human IgG1 antibodies","volume":"53","author":"Hristodorov","year":"2013","journal-title":"Mol Biotechnol"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100155_bib300","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.biologicals.2007.05.003","article-title":"Effect of constant and variable domain glycosylation on pharmacokinetics of therapeutic antibodies in mice","volume":"36","author":"Millward","year":"2008","journal-title":"Biologicals"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100155_bib301","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.4049\/jimmunol.162.4.2162","article-title":"Position effects of variable region carbohydrate on the affinity and in vivo behavior of an anti-(1\u21926) dextran antibody","volume":"162","author":"Coloma","year":"1999","journal-title":"J Immunol"},{"key":"10.1016\/j.pharmr.2026.100155_bib302","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1146\/annurev.immunol.25.022106.141702","article-title":"The impact of glycosylation on the biological function and structure of human immunoglobulins","volume":"25","author":"Arnold","year":"2007","journal-title":"Annu Rev Immunol"},{"issue":"11-12","key":"10.1016\/j.pharmr.2026.100155_bib303","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1016\/j.molimm.2010.04.006","article-title":"Naturally occurring glycan forms of human immunoglobulins G1 and G2","volume":"47","author":"Flynn","year":"2010","journal-title":"Mol Immunol"},{"key":"10.1016\/j.pharmr.2026.100155_bib304","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3389\/fimmu.2020.00021","article-title":"Glycosylated biotherapeutics: immunological effects of N-glycolylneuraminic acid","volume":"11","author":"Yehuda","year":"2020","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100155_bib305","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3892\/ijmm.2015.2397","article-title":"Characteristics of \u03b1-Gal epitope, anti-Gal antibody, \u03b11,3 galactosyltransferase and its clinical exploitation","volume":"37","author":"Huai","year":"2016","journal-title":"Int J Mol Med"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100155_bib306","first-page":"159","article-title":"Immunomodulation by LFA3TIP, an LFA-3\/IgG1 fusion protein: cell line dependent glycosylation effects on pharmacokinetics and pharmacodynamic markers","volume":"2","author":"Meier","year":"1995","journal-title":"Ther Immunol"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100155_bib307","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1016\/j.xphs.2018.11.029","article-title":"The mechanistic impact of N-glycosylation on stability, pharmacokinetics, and immunogenicity of therapeutic proteins","volume":"108","author":"Zhou","year":"2019","journal-title":"J Pharm Sci"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100155_bib308","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/j.xphs.2018.12.014","article-title":"Immunogenicity of protein pharmaceuticals","volume":"108","author":"Dingman","year":"2019","journal-title":"J Pharm Sci"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100155_bib309","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1517\/17460441.2010.514326","article-title":"Immunogenicity of therapeutics: a matter of efficacy and safety","volume":"5","author":"Nechansky","year":"2010","journal-title":"Expert Opin Drug Discov"},{"issue":"Suppl 1","key":"10.1016\/j.pharmr.2026.100155_bib310","first-page":"7","article-title":"Immunogenicity of erythropoietin and other growth factors","author":"Indiveri","year":"2002","journal-title":"Rev Clin Exp Hematol"},{"issue":"suppl 2","key":"10.1016\/j.pharmr.2026.100155_bib311","first-page":"II4","article-title":"Immunogenicity of recombinant human proteins: causes and consequences","volume":"251","author":"Schellekens","year":"2004","journal-title":"J Neurol"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100155_bib312","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s12902-022-00944-5","article-title":"Efficacy and immunogenicity of insulin biosimilar compared to their reference products: a systematic review and meta-analysis","volume":"22","author":"Yang","year":"2022","journal-title":"BMC Endocr Disord"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100155_bib313","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1177\/2042098611406318","article-title":"Immunogenicity and other problems associated with the use of biopharmaceuticals","volume":"2","author":"Tovey","year":"2011","journal-title":"Ther Adv Drug Saf"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100155_bib314","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s40259-016-0174-5","article-title":"Assessing the immunogenicity of biopharmaceuticals","volume":"30","author":"Pineda","year":"2016","journal-title":"BioDrugs"},{"key":"10.1016\/j.pharmr.2026.100155_bib315","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.3389\/fimmu.2020.01951","article-title":"The molecular mechanisms that underlie the immune biology of anti-drug antibody formation following treatment with monoclonal antibodies","volume":"11","author":"Vaisman-Mentesh","year":"2020","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100155_bib316","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.tips.2009.11.001","article-title":"Immunological mechanism underlying the immune response to recombinant human protein therapeutics","volume":"31","author":"Sauerborn","year":"2010","journal-title":"Trends Pharmacol Sci"},{"issue":"suppl 5","key":"10.1016\/j.pharmr.2026.100155_bib317","doi-asserted-by":"crossref","first-page":"v9","DOI":"10.1093\/ndt\/gfl476","article-title":"Immunogenicity of biopharmaceuticals","volume":"21","author":"Kessler","year":"2006","journal-title":"Nephrol Dial Transplant"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100155_bib318","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1097\/MNH.0b013e3282f0c4bf","article-title":"Epoetin-induced pure red cell aplasia: diagnosis and treatment","volume":"16","author":"Macdougall","year":"2007","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1016\/j.pharmr.2026.100155_bib319","article-title":"Case report: dynamic antibody monitoring in a case of anti-recombinant human erythropoietin-mediated pure red cell aplasia with prolonged course after kidney transplantation","volume":"13","author":"Chen","year":"2022","journal-title":"Front Immunol"},{"issue":"10","key":"10.1016\/j.pharmr.2026.100155_bib320","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/j.cgh.2012.06.032","article-title":"Therapeutic drug monitoring of tumor necrosis factor antagonists in inflammatory bowel disease","volume":"10","author":"Ord\u00e1s","year":"2012","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100155_bib321","first-page":"1041","article-title":"Clinical study of recombinant DNA-produced leukocyte interferon (clone A) in a intermittent schedule in cancer patients","volume":"70","author":"Quesada","year":"1983","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100155_bib322","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1089\/dia.2007.0294","article-title":"Immunogenicity of human and bovine insulin in type 1 diabetes mellitus patients","volume":"10","author":"Himanshu","year":"2008","journal-title":"Diabetes Technol Ther"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100155_bib323","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1002\/dmrr.961","article-title":"Circulating insulin antibodies: influence of continuous subcutaneous or intraperitoneal insulin infusion, and impact on glucose control","volume":"25","author":"Radermecker","year":"2009","journal-title":"Diabetes Metab Res Rev"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100155_bib324","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1210\/er.2007-0002","article-title":"Immunological responses to exogenous insulin","volume":"28","author":"Fineberg","year":"2007","journal-title":"Endocr Rev"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100155_bib325","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1208\/s12248-020-00518-0","article-title":"Comparison of the ELISA and ECL assay for vedolizumab anti-drug antibodies: assessing the impact on pharmacokinetics and safety outcomes of the phase 3 Gemini trials","volume":"23","author":"Wyant","year":"2020","journal-title":"AAPS J"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100155_bib326","doi-asserted-by":"crossref","first-page":"3729","DOI":"10.1016\/j.xphs.2019.07.013","article-title":"PKPD assessment of the anti-CD20 antibody obinutuzumab in cynomolgus monkey is feasible despite marked anti-drug antibody response in this species","volume":"108","author":"Grimm","year":"2019","journal-title":"J Pharm Sci"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100155_bib327","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1208\/s12248-016-0033-9","article-title":"An Integrated assessment of the effects of immunogenicity on the pharmacokinetics, safety, and efficacy of elotuzumab","volume":"19","author":"Passey","year":"2017","journal-title":"AAPS J"},{"key":"10.1016\/j.pharmr.2026.100155_bib328","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1406353","article-title":"Characterization of anti-drug antibody responses to the T-cell engaging bispecific antibody cibisatamab to understand the impact on exposure","volume":"15","author":"Lotz","year":"2024","journal-title":"Front Immunol"},{"issue":"9","key":"10.1016\/j.pharmr.2026.100155_bib329","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1111\/apt.14318","article-title":"Significance of measurement of serum trough level and anti-drug antibody of adalimumab as personalised pharmacokinetics in patients with Crohn\u2019s disease: a subanalysis of the DIAMOND trial","volume":"46","author":"Nakase","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100155_bib330","doi-asserted-by":"crossref","DOI":"10.1111\/cts.70166","article-title":"Effect of E7777 immunogenicity on pharmacokinetics, efficacy, and safety in adult patients with relapsed or refractory cutaneous T-cell lymphoma","volume":"18","author":"Thway","year":"2025","journal-title":"Clin Transl Sci"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100155_bib331","first-page":"2421","article-title":"Modification of human leukocyte interferon pharmacology with a monoclonal antibody","volume":"45","author":"Rosenblum","year":"1985","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100155_bib332","article-title":"Emerging technologies and generic assays for the detection of anti-drug antibodies","volume":"2016","author":"Partridge","year":"2016","journal-title":"J Immunol Res"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100155_bib333","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1002\/jcph.1368","article-title":"A mechanism-based population pharmacokinetics model of erythropoietin in premature infants and healthy adults following multiple intravenous doses","volume":"59","author":"D\u2019Cunha","year":"2019","journal-title":"J Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100155_bib334","doi-asserted-by":"crossref","first-page":"366","DOI":"10.2337\/diacare.4.3.366","article-title":"Factors influencing the absorption, serum insulin concentration, and blood glucose responses after injections of regular insulin and various insulin mixtures","volume":"4","author":"Galloway","year":"1981","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100155_bib335","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1055\/s-0028-1093701","article-title":"Prolonged suppression of insulin release by insulin-induced hypoglycemia: demonstration by C-peptide assay","volume":"7","author":"Horwitz","year":"1975","journal-title":"Horm Metab Res"},{"key":"10.1016\/j.pharmr.2026.100155_bib336","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jpba.2015.01.047","article-title":"Development of a lectin binding assay to differentiate between recombinant and endogenous proteins in pharmacokinetic studies of protein-biopharmaceuticals","volume":"108","author":"Weber","year":"2015","journal-title":"J Pharm Biomed Anal"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100155_bib337","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1507\/endocrj1954.21.147","article-title":"Effect of exogenous bonito insulin on endogenous insulin secretion in dogs","volume":"21","author":"Ohgawara","year":"1974","journal-title":"Endocrinol Jpn"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100155_bib338","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/S1096-6374(02)00061-8","article-title":"Pharmacokinetics and acute lipolytic actions of growth hormone. Impact of age, body composition, binding proteins, and other hormones","volume":"12","author":"Hansen","year":"2002","journal-title":"Growth Horm IGF Res"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100155_bib339","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1172\/JCI116669","article-title":"39-kD protein inhibits tissue-type plasminogen activator clearance in vivo","volume":"92","author":"Warshawsky","year":"1993","journal-title":"J Clin Invest"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100155_bib340","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1161\/01.CIR.77.3.660","article-title":"Interactions of tissue-type plasminogen activator with plasma inhibitors and their pharmacologic implications","volume":"77","author":"Lucore","year":"1988","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100155_bib341","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0031-6997(24)01447-9","article-title":"Ligand-binding proteins: their potential for application in systems for controlled delivery and uptake of ligands","volume":"52","author":"de Wolf","year":"2000","journal-title":"Pharmacol Rev"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100155_bib342","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1023\/B:PHAM.0000036926.54824.37","article-title":"The mechanism of protraction of insulin detemir, a long-acting, acylated analog of human insulin","volume":"21","author":"Havelund","year":"2004","journal-title":"Pharm Res"},{"issue":"16","key":"10.1016\/j.pharmr.2026.100155_bib343","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1182\/blood-2016-04-713289","article-title":"Life in the shadow of a dominant partner: the FVIII-VWF association and its clinical implications for hemophilia A","volume":"128","author":"Pipe","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.pharmr.2026.100155_bib344","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/j.ijbiomac.2021.09.151","article-title":"Keratinocyte growth factor in focus: a comprehensive review from structural and functional aspects to therapeutic applications of palifermin","volume":"191","author":"Sadeghi","year":"2021","journal-title":"Int J Biol Macromol"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100155_bib345","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1111\/j.1365-2125.1990.tb03692.x","article-title":"The pharmacokinetics of recombinant human erythropoietin after intravenous and subcutaneous administration to healthy subjects","volume":"29","author":"Salmonson","year":"1990","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100155_bib346","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s00262-007-0377-1","article-title":"Influence of varying doses of granulocyte-macrophage colony-stimulating factor on pharmacokinetics and antibody-dependent cellular cytotoxicity","volume":"57","author":"Liljefors","year":"2008","journal-title":"Cancer Immunol Immunother"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100155_bib347","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1124\/jpet.110.167304","article-title":"Simultaneous pharmacokinetics\/pharmacodynamics modeling of recombinant human erythropoietin upon multiple intravenous dosing in rats","volume":"334","author":"Ait-Oudhia","year":"2010","journal-title":"J Pharmacol Exp Ther"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100155_bib348","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1002\/pbc.20685","article-title":"Pharmacokinetics and pharmacodynamics of intravenous epoetin alfa in children with cancer","volume":"47","author":"Freeman","year":"2006","journal-title":"Pediatr Blood Cancer"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100155_bib349","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1182\/blood.V79.11.2849.2849","article-title":"Pharmacokinetics of subcutaneous recombinant human granulocyte colony-stimulating factor in children","volume":"79","author":"Stute","year":"1992","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100155_bib350","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1002\/cpt.3515","article-title":"Pharmacokinetics of the monoclonal antibody, sotrovimab, in healthy participants following IM administration at different injection sites","volume":"117","author":"El-Zailik","year":"2025","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100155_bib351","doi-asserted-by":"crossref","first-page":"59","DOI":"10.7326\/0003-4819-92-1-59","article-title":"Alterations in insulin absorption and in blood glucose control associated with varying insulin injection sites in diabetic patients","volume":"92","author":"Koivisto","year":"1980","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.pharmr.2026.100155_bib352","first-page":"152","article-title":"Subcutaneous erythropoietin therapy: comparison of three different sites of injection","volume":"vol 88","author":"Macdougall","year":"1991"},{"key":"10.1016\/j.pharmr.2026.100155_bib353","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.jconrel.2021.06.038","article-title":"Impact of injection sites on clinical pharmacokinetics of subcutaneously administered peptides and proteins","volume":"336","author":"Zou","year":"2021","journal-title":"J Control Release"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100155_bib354","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1208\/s12248-020-00460-1","article-title":"Development and application of a physiologically-based pharmacokinetic model to predict the pharmacokinetics of therapeutic proteins from full-term neonates to adolescents","volume":"22","author":"Pan","year":"2020","journal-title":"AAPS J"},{"issue":"9","key":"10.1016\/j.pharmr.2026.100155_bib355","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1007\/s40262-021-01011-3","article-title":"Population pharmacokinetics and pharmacodynamics of once-daily growth hormone Norditropin\u00ae in children and adults","volume":"60","author":"Papathanasiou","year":"2021","journal-title":"Clin Pharmacokinet"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100155_bib356","first-page":"1144","article-title":"Effects of the FcRn developmental pharmacology on the pharmacokinetics of therapeutic monoclonal IgG antibody in pediatric subjects using minimal physiologically-based pharmacokinetic modelling","volume":"10","author":"Hardiansyah","year":"2018","journal-title":"mAbs"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100155_bib357","doi-asserted-by":"crossref","first-page":"e199","DOI":"10.1111\/hae.14622","article-title":"Efficacy, safety and pharmacokinetics of recombinant human coagulation factor VIII (omfiloctocog alfa) in previously treated Chinese children with severe hemophilia A","volume":"28","author":"Wu","year":"2022","journal-title":"Haemophilia"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100155_bib358","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1177\/089686089401400111","article-title":"A multicenter study with once a week or once every two weeks high-dose subcutaneous administration of recombinant human erythropoietin in continuous ambulatory peritoneal dialysis","volume":"14","author":"Nomoto","year":"1994","journal-title":"Perit Dial Int"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100155_bib359","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1681\/ASN.V52177","article-title":"Reduced production, absorption, and elimination of erythropoietin in uremia compared with healthy volunteers","volume":"5","author":"Jensen","year":"1994","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100155_bib360","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1007\/s12325-015-0191-7","article-title":"Clinical pharmacokinetics of the anti-interleukin-20 monoclonal antibody NNC0109-0012 in healthy volunteers and patients with psoriasis or rheumatoid arthritis","volume":"32","author":"Lundblad","year":"2015","journal-title":"Adv Ther"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100155_bib361","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1208\/s12248-014-9599-2","article-title":"Assessment and reporting of the clinical immunogenicity of therapeutic proteins and peptides-harmonized terminology and tactical recommendations","volume":"16","author":"Shankar","year":"2014","journal-title":"AAPS J"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100155_bib362","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1208\/s12248-014-9582-y","article-title":"A white paper-consensus and recommendations of a global harmonization team on assessing the impact of immunogenicity on pharmacokinetic measurements","volume":"16","author":"Sailstad","year":"2014","journal-title":"AAPS J"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100155_bib363","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/BF03190257","article-title":"The relevance of pharmacokinetics in the development of biotechnology products","volume":"21","author":"Toon","year":"1996","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100155_bib364","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1007\/s00216-011-5527-9","article-title":"Attribution of the discrepancy between ELISA and LC-MS\/MS assay results of a pegylated scaffold protein in post-dose monkey plasma samples due to the presence of anti-drug antibodies","volume":"402","author":"Wang","year":"2012","journal-title":"Anal Bioanal Chem"},{"key":"10.1016\/j.pharmr.2026.100155_bib365","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1035556","article-title":"Kinetics of free and ligand-bound atacicept in human serum","volume":"13","author":"Eslami","year":"2022","journal-title":"Front Immunol"},{"issue":"10","key":"10.1016\/j.pharmr.2026.100155_bib366","doi-asserted-by":"crossref","first-page":"2713","DOI":"10.1016\/j.jtha.2024.07.007","article-title":"Characterization of recombinant factor IX fusion proteins enabling subcutaneous administration","volume":"22","author":"Sch\u00f6n","year":"2024","journal-title":"J Thromb Haemost"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100155_bib367","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.jtha.2025.07.013","article-title":"A phase 1, open-label study to assess the pharmacokinetics, safety, and tolerability of a single intravenous injection of efanesoctocog alfa in adults with type 2N or type 3 von Willebrand disease","volume":"24","author":"Susen","year":"2026","journal-title":"J Thromb Haemost"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100155_bib368","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1021\/ac403218f","article-title":"Heteronuclear NMR as a 4-in-1 analytical platform for detecting modification-specific signatures of therapeutic insulin formulations","volume":"86","author":"Jin","year":"2014","journal-title":"Anal Chem"},{"issue":"9","key":"10.1016\/j.pharmr.2026.100155_bib369","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1016\/j.xphs.2022.06.003","article-title":"A full target-mediated drug disposition (TMDD) model to explain the changes in recombinant human erythropoietin (rhEpo) pharmacokinetics in patients with different bone marrow integrity following hematopoietic transplantation","volume":"111","author":"Wu","year":"2022","journal-title":"J Pharm Sci"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100155_bib370","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s10928-024-09922-x","article-title":"Translational two-pore PBPK model to characterize whole-body disposition of different-size endogenous and exogenous proteins","volume":"51","author":"Liu","year":"2024","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"9","key":"10.1016\/j.pharmr.2026.100155_bib371","doi-asserted-by":"crossref","DOI":"10.1038\/psp.2012.4","article-title":"Basic concepts in population modeling, simulation, and model-based drug development","volume":"1","author":"Mould","year":"2012","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100155_bib372","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s10928-012-9280-2","article-title":"Applications of minimal physiologically-based pharmacokinetic models","volume":"39","author":"Cao","year":"2012","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100155_bib373","doi-asserted-by":"crossref","DOI":"10.1111\/cts.70296","article-title":"Population pharmacokinetic and pharmacokinetic-pharmacodynamic modeling of serum M-protein response for Modakafusp Alfa in a Phase 1\/2 study of patients with relapsed or refractory multiple myeloma","volume":"18","author":"Li","year":"2025","journal-title":"Clin Transl Sci"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100155_bib374","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.anai.2021.02.010","article-title":"Population pharmacokinetics of recombinant human C1 esterase inhibitor in children with hereditary angioedema","volume":"126","author":"Hayes","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"9","key":"10.1016\/j.pharmr.2026.100155_bib375","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1016\/j.xphs.2024.06.022","article-title":"Model-based interspecies scaling for predicting human pharmacokinetics of CB 4332, a complement factor I protein","volume":"113","author":"Ayoun Alsoud","year":"2024","journal-title":"J Pharm Sci"},{"issue":"10","key":"10.1016\/j.pharmr.2026.100155_bib376","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1002\/psp4.13159","article-title":"PBPK modeling of recombinant factor IX Fc fusion protein (rFIXFc) and rFIX to characterize the binding to type 4 collagen in the extravascular space","volume":"13","author":"Cloesmeijer","year":"2024","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100155_bib377","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s40262-021-01079-x","article-title":"Real-life population pharmacokinetics of recombinant factor XIII and dosing considerations for preventing the risk of bleeding in patients with FXIII congenital deficiency","volume":"61","author":"Cojutti","year":"2022","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100155_bib378","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1002\/cpt.3524","article-title":"Population pharmacokinetic\/pharmacodynamic and exposure-response modeling analyses of sotatercept in healthy participants and patients with pulmonary arterial hypertension","volume":"117","author":"Ait-Oudhia","year":"2025","journal-title":"Clin Pharmacol Ther"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100155_bib379","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1080\/00498254.2022.2133649","article-title":"Application of physiologically based pharmacokinetic models for therapeutic proteins and other novel modalities","volume":"52","author":"Rose","year":"2022","journal-title":"Xenobiotica"},{"issue":"9","key":"10.1016\/j.pharmr.2026.100155_bib380","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1002\/psp4.70080","article-title":"Mechanism-based modeling approaches to quantify the effect of immunogenicity on the pharmacokinetics of therapeutic proteins in drug development","volume":"14","author":"Gupta","year":"2025","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100155_bib381","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1039\/D1CB00067E","article-title":"Aggregation of protein therapeutics enhances their immunogenicity: causes and mitigation strategies","volume":"2","author":"Lundahl","year":"2021","journal-title":"RSC Chem Biol"},{"key":"10.1016\/j.pharmr.2026.100155_bib382","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2020.119523","article-title":"Protein aggregation and immunogenicity of biotherapeutics","volume":"585","author":"Pham","year":"2020","journal-title":"Int J Pharm"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100155_bib383","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0085281","article-title":"Influence of aggregation and route of injection on the biodistribution of mouse serum albumin","volume":"9","author":"Kijanka","year":"2014","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100155_bib384","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1124\/dmd.123.001555","article-title":"Correlation of in vitro kinetic stability to preclinical in vivo pharmacokinetics for a panel of anti-PD-1 monoclonal antibody interleukin 21 mutein immunocytokines","volume":"52","author":"Cook","year":"2024","journal-title":"Drug Metab Dispos"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100155_bib385","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1038\/nbt1029","article-title":"Recombinant protein folding and misfolding in Escherichia coli","volume":"22","author":"Baneyx","year":"2004","journal-title":"Nat Biotechnol"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100155_bib386","doi-asserted-by":"crossref","first-page":"235","DOI":"10.3390\/biom4010235","article-title":"Refolding techniques for recovering biologically active recombinant proteins from inclusion bodies","volume":"4","author":"Yamaguchi","year":"2014","journal-title":"Biomolecules"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100155_bib387","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1002\/iub.215","article-title":"Unraveling the mysteries of endostatin","volume":"61","author":"Fu","year":"2009","journal-title":"IUBMB Life"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100155_bib388","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.tibtech.2019.12.011","article-title":"Bacterial inclusion bodies: a treasure trove of bioactive proteins","volume":"38","author":"Singhvi","year":"2020","journal-title":"Trends Biotechnol"},{"issue":"S2","key":"10.1016\/j.pharmr.2026.100155_bib389","first-page":"S21","article-title":"Ever-increasing insulin-requiring patients globally","volume":"20","author":"Garg","year":"2018","journal-title":"Diabetes Technol Ther"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100155_bib390","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1124\/jpet.122.001105","article-title":"Preclinical characterization of LY3209590, a novel weekly basal insulin Fc-fusion protein","volume":"382","author":"Moyers","year":"2022","journal-title":"J Pharmacol Exp Ther"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100155_bib391","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1111\/dom.14956","article-title":"Pharmacokinetic and pharmacodynamic properties of the novel basal insulin Fc (insulin efsitora alfa), an insulin fusion protein in development for once-weekly dosing for the treatment of patients with diabetes","volume":"25","author":"Heise","year":"2023","journal-title":"Diabetes Obes Metab"},{"issue":"10458","key":"10.1016\/j.pharmr.2026.100155_bib392","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1016\/S0140-6736(24)01804-X","article-title":"Once-weekly insulin efsitora alfa versus once-daily insulin degludec in adults with type 1 diabetes (QWINT-5): a phase 3 randomised non-inferiority trial","volume":"404","author":"Bergenstal","year":"2024","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100155_bib393","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1056\/NEJMoa2502796","article-title":"Weekly fixed-dose insulin efsitora in type 2 diabetes without previous insulin therapy","volume":"393","author":"Rosenstock","year":"2025","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100155_bib394","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.beem.2016.06.004","article-title":"Managing hypoglycaemia","volume":"30","author":"Iqbal","year":"2016","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"10","key":"10.1016\/j.pharmr.2026.100155_bib395","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1038\/s41551-023-01138-7","article-title":"Week-long normoglycaemia in diabetic mice and minipigs via a subcutaneous dose of a glucose-responsive insulin complex","volume":"8","author":"Zhang","year":"2024","journal-title":"Nat Biomed Eng"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100155_bib396","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1021\/jacs.3c10941","article-title":"Improving protein expression, stability, and function with ProteinMPNN","volume":"146","author":"Sumida","year":"2024","journal-title":"J Am Chem Soc"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100155_bib397","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1038\/s41551-021-00699-9","article-title":"Optimization of therapeutic antibodies by predicting antigen specificity from antibody sequence via deep learning","volume":"5","author":"Mason","year":"2021","journal-title":"Nat Biomed Eng"},{"key":"10.1016\/j.pharmr.2026.100155_bib398","article-title":"Inverse folding of protein complexes with a structure-informed language model enables unsupervised antibody evolution","author":"Shanker","year":"2023","journal-title":"bioRxiv"},{"issue":"14","key":"10.1016\/j.pharmr.2026.100155_bib399","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241411564","article-title":"Impact of E484Q and L452R mutations on structure and binding behavior of SARS-CoV-2 B.1.617.1 using deep Learning AlphaFold2, molecular docking and dynamics simulation","volume":"24","author":"Jiao","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100155_bib400","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1038\/s41587-024-02127-0","article-title":"Machine learning for functional protein design","volume":"42","author":"Notin","year":"2024","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.pharmr.2026.100155_bib401","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1275999","article-title":"Development of anti-PD-L1 antibody based on structure prediction of AlphaFold2","volume":"14","author":"Du","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.pharmr.2026.100155_bib402","article-title":"AI models for protein design are driving antibody engineering","volume":"28","author":"Chungyoun","year":"2023","journal-title":"Curr Opin Biomed Eng"},{"issue":"9","key":"10.1016\/j.pharmr.2026.100155_bib403","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.3390\/pharmaceutics14091769","article-title":"Computation-aided design of albumin Affibody-inserted antibody fragment for the prolonged serum half-life","volume":"14","author":"Kwon","year":"2022","journal-title":"Pharmaceutics"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100155_bib404","first-page":"216","article-title":"Designing and evaluation of a novel IL-1RA fusion cytokine to enhance the pharmacokinetics and receptor affinity for better therapeutic intervention in inflammatory disorders","volume":"22","author":"Rajendran","year":"2026","journal-title":"Curr Comput Aided Drug Des"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100155_bib405","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1021\/acs.bioconjchem.2c00176","article-title":"Impacts of a zwitterionic peptide on its fusion protein","volume":"33","author":"McMullen","year":"2022","journal-title":"Bioconjug Chem"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100155_bib406","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/s41587-023-01705-y","article-title":"AI-enhanced protein design makes proteins that have never existed","volume":"41","author":"Eisenstein","year":"2023","journal-title":"Nat Biotechnol"},{"issue":"7738","key":"10.1016\/j.pharmr.2026.100155_bib407","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/s41586-018-0830-7","article-title":"De novo design of potent and selective mimics of IL-2 and IL-15","volume":"565","author":"Silva","year":"2019","journal-title":"Nature"},{"issue":"6681","key":"10.1016\/j.pharmr.2026.100155_bib408","doi-asserted-by":"crossref","DOI":"10.1126\/science.ado1671","article-title":"Protein design meets biosecurity","volume":"383","author":"Baker","year":"2024","journal-title":"Science"},{"issue":"8037","key":"10.1016\/j.pharmr.2026.100155_bib409","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1038\/d41586-024-03595-9","article-title":"Five protein-design questions that still challenge AI","volume":"635","author":"Reardon","year":"2024","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100155_bib410","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2025.2547084","article-title":"Machine learning-driven optimization of culture conditions and media components to mitigate charge heterogeneity in monoclonal antibody production: current advances and future perspectives","volume":"17","author":"Kavoni","year":"2025","journal-title":"mAbs"},{"key":"10.1016\/j.pharmr.2026.100155_bib411","doi-asserted-by":"crossref","DOI":"10.1016\/j.biotechadv.2024.108480","article-title":"Recent advances in culture medium design for enhanced production of monoclonal antibodies in CHO cells: a comparative study of machine learning and systems biology approaches","volume":"78","author":"Kavoni","year":"2025","journal-title":"Biotechnol Adv"},{"key":"10.1016\/j.pharmr.2026.100155_bib412","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.1016\/j.csbj.2022.06.006","article-title":"PERISCOPE-Opt: machine learning-based prediction of optimal fermentation conditions and yields of recombinant periplasmic protein expressed in Escherichia coli","volume":"20","author":"Packiam","year":"2022","journal-title":"Comput Struct Biotechnol J"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100155_bib413","doi-asserted-by":"crossref","DOI":"10.1002\/btpr.3249","article-title":"Smart process development: application of machine-learning and integrated process modeling for inclusion body purification processes","volume":"38","author":"Walther","year":"2022","journal-title":"Biotechnol Prog"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100155_bib414","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1011939","article-title":"Combining machine learning with structure-based protein design to predict and engineer post-translational modifications of proteins","volume":"20","author":"Ertelt","year":"2024","journal-title":"PLoS Comput Biol"},{"key":"10.1016\/j.pharmr.2026.100155_bib415","doi-asserted-by":"crossref","DOI":"10.1016\/j.compbiolchem.2021.107596","article-title":"Deep protein representations enable recombinant protein expression prediction","volume":"95","author":"Martiny","year":"2021","journal-title":"Comput Biol Chem"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100155_bib416","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1007\/s11095-024-03742-x","article-title":"Machine learning prediction of on\/off target-driven clinical adverse events","volume":"41","author":"Cao","year":"2024","journal-title":"Pharm Res"},{"key":"10.1016\/j.pharmr.2026.100155_bib417","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1016\/j.csbj.2025.04.002","article-title":"ToxDL 2.0: protein toxicity prediction using a pretrained language model and graph neural networks","volume":"27","author":"Zhu","year":"2025","journal-title":"Comput Struct Biotechnol J"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100155_bib418","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s00253-004-1559-9","article-title":"Secretory and extracellular production of recombinant proteins using Escherichia coli","volume":"64","author":"Choi","year":"2004","journal-title":"Appl Microbiol Biotechnol"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100155_bib419","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s12934-018-0901-3","article-title":"Signal peptides for recombinant protein secretion in bacterial expression systems","volume":"17","author":"Freudl","year":"2018","journal-title":"Microb Cell Fact"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100155_bib420","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1016\/j.apsb.2022.12.008","article-title":"Endothelial METRNL determines circulating METRNL level and maintains endothelial function against atherosclerosis","volume":"13","author":"Zheng","year":"2023","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.pharmr.2026.100155_bib421","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2024.108730","article-title":"Metrnl as a secreted protein: discovery and cardiovascular research","volume":"263","author":"Miao","year":"2024","journal-title":"Pharmacol Ther"},{"issue":"12","key":"10.1016\/j.pharmr.2026.100155_bib422","doi-asserted-by":"crossref","first-page":"4011","DOI":"10.2337\/db15-0274","article-title":"Adipocyte metrnl antagonizes insulin resistance through PPAR\u03b3 signaling","volume":"64","author":"Li","year":"2015","journal-title":"Diabetes"},{"issue":"10","key":"10.1016\/j.pharmr.2026.100155_bib423","doi-asserted-by":"crossref","DOI":"10.15252\/embr.201745517","article-title":"Serum amyloid A promotes LPS clearance and suppresses LPS-induced inflammation and tissue injury","volume":"19","author":"Cheng","year":"2018","journal-title":"EMBO Rep"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100155_bib424","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1124\/pr.114.009373","article-title":"Antibody drug conjugates for cancer therapy","volume":"68","author":"Polakis","year":"2016","journal-title":"Pharmacol Rev"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100155_bib425","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1124\/pharmrev.123.001084","article-title":"Precision medicine in rheumatic diseases: unlocking the potential of antibody-drug conjugates","volume":"76","author":"Huang","year":"2024","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.pharmr.2026.100155_bib426","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2025.102922","article-title":"Pharmacology and pharmacokinetics of antibody-drug conjugates, where do we stand?","volume":"135","author":"G\u00e9raud","year":"2025","journal-title":"Cancer Treat Rev"},{"issue":"1-2","key":"10.1016\/j.pharmr.2026.100155_bib427","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1080\/17425255.2024.2302460","article-title":"Pharmacokinetics and pharmacodynamics of antibody-drug conjugates for the treatment of patients with breast cancer","volume":"20","author":"Cherifi","year":"2024","journal-title":"Expert Opin Drug Metab Toxicol"}],"container-title":["Pharmacological Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031699726000438?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031699726000438?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T19:45:49Z","timestamp":1790365549000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0031699726000438"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":427,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S0031699726000438"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmr.2026.100155","relation":{},"ISSN":["0031-6997"],"issn-type":[{"value":"0031-6997","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recombinant protein drug metabolism and pharmacokinetics","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmr.2026.100155","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of American Society for Pharmacology and Experimental Therapeutics.","name":"copyright","label":"Copyright"}],"article-number":"100155"}}